<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN"  "JATS-archivearticle1-mathml3.dtd"><?covid-19-tdm ?><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.2"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic" pub-type="epub">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">85264</article-id><article-id pub-id-type="doi">10.7554/eLife.85264</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Epidemiology and Global Health</subject></subj-group></article-categories><title-group><article-title>Projected long-term effects of colorectal cancer screening disruptions following the COVID-19 pandemic</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" id="author-299914"><name><surname>Nascimento de Lima</surname><given-names>Pedro</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-9057-198X</contrib-id><email>plima@rand.org</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-300352"><name><surname>van den Puttelaar</surname><given-names>Rosita</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-2216-6557</contrib-id><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="fund1"/><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-300353"><name><surname>Hahn</surname><given-names>Anne I</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-4061-2303</contrib-id><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund2"/><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-300354"><name><surname>Harlass</surname><given-names>Matthias</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="fund1"/><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-255792"><name><surname>Collier</surname><given-names>Nicholson</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-2376-4156</contrib-id><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="other" rid="fund1"/><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-255796"><name><surname>Ozik</surname><given-names>Jonathan</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-3495-6735</contrib-id><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="other" rid="fund3"/><xref ref-type="other" rid="fund1"/><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-251614"><name><surname>Zauber</surname><given-names>Ann G</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-1764-5994</contrib-id><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="other" rid="fund1"/><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-300355"><name><surname>Lansdorp-Vogelaar</surname><given-names>Iris</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="fund1"/><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-300356"><name><surname>Rutter</surname><given-names>Carolyn M</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-4396-8594</contrib-id><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="other" rid="fund1"/><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00f2z7n96</institution-id><institution>RAND Corporation</institution></institution-wrap><addr-line><named-content content-type="city">Santa Monica</named-content></addr-line><country>United States</country></aff><aff id="aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/018906e22</institution-id><institution>Erasmus MC</institution></institution-wrap><addr-line><named-content content-type="city">Rotterdam</named-content></addr-line><country>Netherlands</country></aff><aff id="aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02yrq0923</institution-id><institution>Memorial Sloan Kettering Cancer Center</institution></institution-wrap><addr-line><named-content content-type="city">New York</named-content></addr-line><country>United States</country></aff><aff id="aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/05gvnxz63</institution-id><institution>Argonne National Laboratory</institution></institution-wrap><addr-line><named-content content-type="city">Lemont</named-content></addr-line><country>United States</country></aff><aff id="aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/007ps6h72</institution-id><institution>Fred Hutchinson Cancer Center</institution></institution-wrap><addr-line><named-content content-type="city">Seattle, WA</named-content></addr-line><country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Franco</surname><given-names>Eduardo L</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01pxwe438</institution-id><institution>McGill University</institution></institution-wrap><country>Canada</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Franco</surname><given-names>Eduardo L</given-names></name><role>Senior Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01pxwe438</institution-id><institution>McGill University</institution></institution-wrap><country>Canada</country></aff></contrib></contrib-group><pub-date publication-format="electronic" date-type="publication"><day>02</day><month>05</month><year>2023</year></pub-date><pub-date pub-type="collection"><year>2023</year></pub-date><volume>12</volume><elocation-id>e85264</elocation-id><history><date date-type="received" iso-8601-date="2022-11-30"><day>30</day><month>11</month><year>2022</year></date><date date-type="accepted" iso-8601-date="2023-04-10"><day>10</day><month>04</month><year>2023</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint at bioRxiv.</event-desc><date date-type="preprint" iso-8601-date="2022-12-26"><day>26</day><month>12</month><year>2022</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2022.12.23.22283887"/></event></pub-history><permissions><copyright-statement>© 2023, Nascimento de Lima et al</copyright-statement><copyright-year>2023</copyright-year><copyright-holder>Nascimento de Lima et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-85264-v1.pdf"/><self-uri content-type="figures-pdf" xlink:href="elife-85264-figures-v1.pdf"/><abstract><p>The aftermath of the initial phase of the COVID-19 pandemic may contribute to the widening of disparities in colorectal cancer (CRC) outcomes due to differential disruptions to CRC screening. This comparative microsimulation analysis uses two CISNET CRC models to simulate the impact of ongoing screening disruptions induced by the COVID-19 pandemic on long-term CRC outcomes. We evaluate three channels through which screening was disrupted: delays in screening, regimen switching, and screening discontinuation. The impact of these disruptions on long-term CRC outcomes was measured by the number of life-years lost due to CRC screening disruptions compared to a scenario without any disruptions. While short-term delays in screening of 3–18 months are predicted to result in minor life-years loss, discontinuing screening could result in much more significant reductions in the expected benefits of screening. These results demonstrate that unequal recovery of screening following the pandemic can widen disparities in CRC outcomes and emphasize the importance of ensuring equitable recovery to screening following the pandemic.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>colorectal cancer</kwd><kwd>COVID-19</kwd><kwd>microsimulation</kwd><kwd>cancer screening</kwd><kwd>comparative modeling</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000054</institution-id><institution>National Cancer Institute</institution></institution-wrap></funding-source><award-id>U01-CA253913</award-id><principal-award-recipient><name><surname>van den Puttelaar</surname><given-names>Rosita</given-names></name><name><surname>Hahn</surname><given-names>Anne I</given-names></name><name><surname>Harlass</surname><given-names>Matthias</given-names></name><name><surname>Collier</surname><given-names>Nicholson</given-names></name><name><surname>Ozik</surname><given-names>Jonathan</given-names></name><name><surname>Zauber</surname><given-names>Ann G</given-names></name><name><surname>Lansdorp-Vogelaar</surname><given-names>Iris</given-names></name><name><surname>Rutter</surname><given-names>Carolyn M</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution>NIH/NCI Cancer Center Support Grant</institution></institution-wrap></funding-source><award-id>P30 CA008748</award-id><principal-award-recipient><name><surname>Hahn</surname><given-names>Anne I</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution>DOE Office of Science User Facility</institution></institution-wrap></funding-source><award-id>DE-AC02-06CH11357</award-id><principal-award-recipient><name><surname>Ozik</surname><given-names>Jonathan</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>Unequal recovery in colorectal cancer screening following the COVID-19 pandemic can widen disparities in colorectal cancer outcomes.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>The novel SARS-Cov-2 (COVID-19) pandemic has resulted in major health consequences across the globe. In addition to the over 1 million COVID-19 deaths in the United States (<xref ref-type="bibr" rid="bib10">Johns Hopkins Univerity &amp; Medicine Coronavirus Resource Center, 2022</xref>), the pandemic has also contributed to steep declines in cancer screening, most notably in the early phases of the pandemic due to government-mandated shutdowns of non-emergency medical services (<xref ref-type="bibr" rid="bib9">Gupta et al., 2020</xref>). It is estimated that colorectal cancer (CRC) screening decreased by 85% in the United States during the early phase of the pandemic, from March through April 2020 (<xref ref-type="bibr" rid="bib16">London et al., 2022</xref>). The pandemic continues to affect CRC screening and diagnosis through staff shortages that reduce capacity at gastroenterology clinics and patient hesitancy to seek care (<xref ref-type="bibr" rid="bib27">Wilensky, 2022</xref>; <xref ref-type="bibr" rid="bib4">Del Vecchio Blanco et al., 2020</xref>). Despite cancer screening reopening efforts, CRC screening has not yet returned to pre-pandemic levels (<xref ref-type="bibr" rid="bib19">Ong, 2021</xref>).</p><p>CRC remains the second-leading cause of cancer deaths in the United States, with approximately 153,020 new cases and 52,550 deaths estimated in the year 2023 (<xref ref-type="bibr" rid="bib24">Siegel et al., 2023</xref>). There is clear evidence that screening has a major impact on reducing the burden of CRC (<xref ref-type="bibr" rid="bib5">Edwards et al., 2010</xref>; <xref ref-type="bibr" rid="bib30">Zauber et al., 2012</xref>) and that it is cost-effective (<xref ref-type="bibr" rid="bib12">Knudsen et al., 2021</xref>; <xref ref-type="bibr" rid="bib13">Lansdorp-Vogelaar et al., 2011</xref>). The current United States Preventive Task Force (USPSTF) report recommends multiple screening options, including annual fecal immunochemical tests (FIT) and colonoscopy every 10 years for average-risk individuals (<xref ref-type="bibr" rid="bib3">Davidson et al., 2021</xref>). However, CRC screening uptake was of concern even before the pandemic, with CRC screening rates well below the goal of 70.5% for Healthy People 2020 and the National Colorectal Cancer Roundtable goal of 80% by 2018 (<xref ref-type="bibr" rid="bib23">Shapiro et al., 2021</xref>). Low rates of CRC screening have been exacerbated by the COVID-19 pandemic, and delays in screening will result in delays in diagnosis, stage progression, and increased CRC mortality.</p><p>The pandemic may also further exacerbate existing disparities related to screening. The burden of unemployment and associated loss of access to healthcare varies across different racial and ethnic groups (<xref ref-type="bibr" rid="bib18">Marcondes et al., 2021</xref>). Because of this, the pandemic may contribute to widening disparities in cancer outcomes. A recent analysis using National Health Interview Survey (NHIS) data postulated that unemployment was adversely associated with being up-to-date with screening, with only 16.7% of unemployed individuals participating in recent CRC screenings, only 48.5% of whom were up-to-date with CRC screening (<xref ref-type="bibr" rid="bib6">Fedewa et al., 2022</xref>).</p><p>The objective of this study is to estimate the impact of ongoing screening and treatment disruptions induced by the COVID-19 pandemic on long-term CRC outcomes. We examine 25 scenarios that reflect different levels of pre-pandemic adherence to colonoscopy and FIT screening to assess how unequal recovery in screening may contribute to widening disparities in CRC lifetime outcomes.</p></sec><sec id="s2" sec-type="methods"><title>Methods</title><p>This paper uses two independently developed microsimulation models of CRC, CRC-SPIN and MISCAN-Colon, to estimate the effects of pandemic-induced disruptions in colonoscopy screening for eight pre-pandemic average-CRC risk population cohorts in the United States. CRC-SPIN and MISCAN-Colon models are part of the National Cancer Institute’s CISNET consortium and describe the natural history of CRC in an unscreened population based on the adenoma-carcinoma sequence. Detailed descriptions of these models and underlying assumptions may be found elsewhere (<xref ref-type="bibr" rid="bib12">Knudsen et al., 2021</xref>; <xref ref-type="bibr" rid="bib15">Loeve et al., 1999</xref>; <xref ref-type="bibr" rid="bib21">Rutter et al., 2019</xref>, <xref ref-type="bibr" rid="bib25">van Hees et al., 2014</xref>). We consider variations on two commonly used screening strategies in the USPSTF recommendations during the onset of the pandemic in March 2020 (<xref ref-type="bibr" rid="bib11">Knudsen et al., 2016</xref>): Decennial colonoscopy from age 50 to 70 and annual FIT from age 50 to 75, with diagnostic colonoscopy after a positive FIT.</p><sec id="s2-1"><title>Cohorts</title><p>We simulated eight pre-pandemic population cohorts that represent average-risk individuals in the United States, defined by both cohort members’ age in April 2020 and their pre-pandemic screening regimens: (i) unscreened 50-year-olds (U50), (ii) unscreened 60-year-olds (U60), (iii) colonoscopy screening-adherent 60-year-olds (C60, who received their first screening colonoscopy at age 50 but have not yet had a colonoscopy at age 60), (iv) FIT screening-adherent 60-year-olds (F60, who performed annual FIT from age 50 to 59), (v) FIT screening semi-adherent 60-year-olds (f60) – those who received biannual FIT from age 50 to 56, (vi) unscreened 70-year-olds (U70), (vii) colonoscopy screening-adherent 70-year-olds (C70, who received screening colonoscopies at age 50 and 60), and (viii) FIT screening-adherent 70-year-olds (F70, who performed annual FIT from age 50 to 69). We simulated 10 million individuals within each cohort to reduce the stochastic variability in our runs and to ensure sufficient precision in our estimates. For each cohort, we simulated three sets of post-pandemic scenarios: no disruption, delays, and no screening.</p></sec><sec id="s2-2"><title>Screening regimens under no disruption</title><p>The <italic>no-disruption</italic> scenarios simulate post-pandemic screening scenarios for each cohort in the counterfactual scenario where no pandemic-induced screening disruptions occurred. In no-disruption scenarios, all these cohorts would have been screened during the pandemic first lockdowns in March 2020. Cohorts with colonoscopy and FIT adherent individuals (U50, C60, F60 C70, F70) continue to follow guideline-recommended strategies strictly, with no delays. Cohorts with delayed initiation (U60, U70) begin screening late but otherwise follow guideline-recommended strategies with no delays but without any additional screening beyond the usual stopping age. Finally, for the <italic>FIT-semi-adherent 60-year-olds</italic> (f60), we simulate resumption of biannual FIT at age 60, continuing to age 75.</p></sec><sec id="s2-3"><title>Pandemic-induced disruptions in CRC screening</title><sec id="s2-3-1"><title>Delays</title><p>The pandemic has been shown to affect CRC outcomes through <italic>delays</italic> in screening. Screening colonoscopy and FIT are assumed to be delayed for a set duration of months starting at the onset of the COVID-19 pandemic in April 2020. Short-term screening delays may have occurred for a series of reasons. First, elective procedures were postponed during the first months of the pandemic. The cancellation of elective procedures caused a sharp decline in CRC screening exams during the initial phase of the pandemic (<xref ref-type="bibr" rid="bib8">Gupta and Lieberman, 2020</xref>). To represent the full spectrum of delays caused by the pandemic – either due to cancellation of elective procedures or disruption in access to healthcare – we consider three sets of delays: a 3-, 9-, or 18-month delay in screening, which we label as <italic>short-term</italic> delays. For each delay scenario, the delay was applied on the first post-March 2020 screening exam and carried forward to any subsequent exams.</p><p>Second, the pandemic may have caused <italic>long-term delays</italic> in CRC screening. While the recovery in screening rates among insured individuals was rapid, (<xref ref-type="bibr" rid="bib2">Choy et al., 2022</xref>) the pandemic also caused a sharp economic recession. The uneven recovery in labor force participation has the potential to cause disparities in access to healthcare in the United States due to unemployment and discontinuation of health insurance. To examine these longer-term effects of the pandemic, we consider scenarios where screening is paused for an extended period. For the 50- and 60-year-old cohorts, we simulated scenarios where screening is discontinued until the start age of Medicare enrollment (65 years). For 70-year-olds, we consider a scenario where screening is only resumed at age 75 – 5 years after the pandemic onset.</p></sec><sec id="s2-3-2"><title>Screening regimen switching</title><p>The pandemic may also affect CRC behavior via screening <italic>regimen switching –</italic> that is, changing from a colonoscopy screening regimen to one based on FIT. There is evidence that during the pandemic some patients switched from colonoscopy to FIT (<xref ref-type="bibr" rid="bib6">Fedewa et al., 2022</xref>) to reduce the need for in-person endoscopy procedures. Considering this possibility, we model scenarios where individuals who initially participated in a regimen of screening colonoscopy (C60 and C70) permanently switch from decennial colonoscopy to annual FIT screening as a boundary case. While one might expect pandemic-induced regimen switching to be temporary, permanent switching can serve as a boundary case for our analysis – that is, the effect of short-term regimen switching is expected to be lower than the effect of permanent regimen switching.</p></sec><sec id="s2-3-3"><title>Screening discontinuation</title><p>We also simulate scenarios where screening is completely discontinued after the pandemic onset as the most consequential boundary case scenario. While only a small (unknown) proportion of individuals will discontinue screening after the pandemic, this scenario serves as an upper bound for the worst possible disruption in CRC screening following the pandemic.</p></sec><sec id="s2-3-4"><title>Scenarios</title><p>Each of the scenarios simulated in this study results from the combination of a pre-pandemic population cohort, a no-disruption screening scenario that serves as a counterfactual, and one or more screening disruptions (i.e. switching to FIT screening occurred in tandem with short-term delays). <xref ref-type="table" rid="table1">Table 1</xref> lists those combinations and the scenario labels used in this analysis. We code our scenarios as <italic>[pre-pandemic screening cohort] | [post-pandemic disruptions]</italic>.</p><table-wrap id="table1" position="float"><label>Table 1.</label><caption><title>Study cohorts and scenarios.</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="top" rowspan="2">Cohort</th><th align="left" valign="top" rowspan="2">No-disruption counterfactual</th><th align="left" valign="top" colspan="2">CRC screening disruption scenario</th></tr><tr><th align="left" valign="top">Description</th><th align="left" valign="top">Label</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="3">Unscreened<break/>50-year-olds (U50)</td><td align="left" valign="top" rowspan="2">Decennial COL from age 50 to 70</td><td align="left" valign="top">Short-term delays of [d] months<sup><xref ref-type="table-fn" rid="table1fn2">*</xref></sup></td><td align="left" valign="top">U50 | C[d]m</td></tr><tr><td align="left" valign="top">Long-term delay (COL at age 65 and 75)</td><td align="left" valign="top">U50 | C@65</td></tr><tr><td align="left" valign="top">Annual FIT from age 50 to 75</td><td align="left" valign="top">Short-term delays<sup><xref ref-type="table-fn" rid="table1fn2">*</xref></sup></td><td align="left" valign="top">U50 | F[d]m</td></tr><tr><td align="left" valign="top" rowspan="3">Unscreened<break/>60-year-olds (U60)</td><td align="left" valign="top" rowspan="2">Decennial COL from age 60 to 70</td><td align="left" valign="top">Short-term delays<sup><xref ref-type="table-fn" rid="table1fn2">*</xref></sup></td><td align="left" valign="top">U60 | C[d]m</td></tr><tr><td align="left" valign="top">Long-term delay (COL at age 65 and 75)</td><td align="left" valign="top">U60 | C@65</td></tr><tr><td align="left" valign="top">Annual FIT from age 60 to 75</td><td align="left" valign="top">Short-term delays<sup><xref ref-type="table-fn" rid="table1fn2">*</xref></sup></td><td align="left" valign="top">U60 | F[d]m</td></tr><tr><td align="left" valign="top" rowspan="4">COL-adherent<break/>60-year-olds (C60)</td><td align="left" valign="top" rowspan="4">Decennial COL from age 50 to 70</td><td align="left" valign="top">Short-term delays<sup><xref ref-type="table-fn" rid="table1fn2">*</xref></sup></td><td align="left" valign="top">C60 | C[d]m</td></tr><tr><td align="left" valign="top">Switch to annual FIT and short-term delays</td><td align="left" valign="top">C60 | F[d]m</td></tr><tr><td align="left" valign="top">Long-term delay (COL at age 65 and 75)</td><td align="left" valign="top">C60 | C@65</td></tr><tr><td align="left" valign="top">Discontinue screening</td><td align="left" valign="top">C60 | U</td></tr><tr><td align="left" valign="top" rowspan="2">FIT-adherent<break/>60-year-olds (F60)</td><td align="left" valign="top" rowspan="2">Annual FIT from age 50 to 75</td><td align="left" valign="top">Short-term delays<sup><xref ref-type="table-fn" rid="table1fn2">*</xref></sup></td><td align="left" valign="top">F60 | F[d]m</td></tr><tr><td align="left" valign="top">Discontinue screening</td><td align="left" valign="top">F60 | U</td></tr><tr><td align="left" valign="top" rowspan="2">FIT-semi-adherent<break/>60-year-olds (f60)</td><td align="left" valign="top" rowspan="2">Biannual FIT from age 50 to 56, annual FIT from age 60 to 75</td><td align="left" valign="top">Short-term delays<sup><xref ref-type="table-fn" rid="table1fn2">*</xref></sup></td><td align="left" valign="top">f60 | F[d]m</td></tr><tr><td align="left" valign="top">Discontinue screening</td><td align="left" valign="top">f60 | U</td></tr><tr><td align="left" valign="top" rowspan="3">Unscreened<break/>70-year-olds (U70)</td><td align="left" valign="top" rowspan="2">COL at age 70</td><td align="left" valign="top">Short-term delays<sup><xref ref-type="table-fn" rid="table1fn2">*</xref></sup></td><td align="left" valign="top">U70 | C[d]m</td></tr><tr><td align="left" valign="top">Long-term delay (COL at age 75)</td><td align="left" valign="top">U70 | C@75</td></tr><tr><td align="left" valign="top">Annual FIT from age 70 to 75</td><td align="left" valign="top">Short-term delays</td><td align="left" valign="top">U70 | F[d]m</td></tr><tr><td align="left" valign="top" rowspan="4">COL-adherent<break/>70-year-olds (C70)</td><td align="left" valign="top" rowspan="4">Decennial COL from age 50 to 70</td><td align="left" valign="top">Short-term delays<sup><xref ref-type="table-fn" rid="table1fn2">*</xref></sup></td><td align="left" valign="top">C70 | C[d]m</td></tr><tr><td align="left" valign="top">Switch to annual FIT and short-term delays</td><td align="left" valign="top">C70 | F[d]m</td></tr><tr><td align="left" valign="top">Long-term delay<break/>Perform COL at age 75</td><td align="left" valign="top">C70 | C@75</td></tr><tr><td align="left" valign="top">Discontinue screening</td><td align="left" valign="top">C70 | U</td></tr><tr><td align="left" valign="top" rowspan="2">FIT-adherent<break/>70-year-olds (F70)</td><td align="left" valign="top" rowspan="2">Annual FIT from age 50 to 75</td><td align="left" valign="top">Short-term delays<sup><xref ref-type="table-fn" rid="table1fn2">*</xref></sup></td><td align="left" valign="top">F70 | F[d]m</td></tr><tr><td align="left" valign="top">Discontinue screening</td><td align="left" valign="top">F70 | U</td></tr></tbody></table><table-wrap-foot><fn><p>Notes: This table presents the scenarios considered in this study. Each scenario corresponds to a combination of a population cohort, indicated by their age during the first COVID-19 lockdowns (March 2020), a pre-pandemic, and a post-pandemic screening regimen. The scenarios aim to represent possible combinations of screening regimens followed in the United States. The first letter in the scenario code represents screening before the pandemic and the second letter represents screening after the pandemic.</p></fn><fn id="table1fn2"><label>*</label><p>Delays of 3, 9, and 18 months. Letter d stands for the number of months of delays.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s2-3-5"><title>Outcomes</title><p>The primary measure used to assess the benefit of CRC screening programs is the expected lifetime life-years gained (LYG) from screening. All outcomes in this study correspond to expected value of life-years (LY) across the US population with average CRC risk. This study investigates the extent to which benefits from screening are expected to be lost due to pandemic-induced disruptions to CRC screening. Therefore, we calculated the total number of LY for each cohort and scenario, including the number of LY under no screening (LYNS) and the number of LY under no disruptions (LYND). LYNS is computed by simulating the cohort in the absence of CRC screening and LYND is computed by simulating the same cohort under an ideal screening scenario where no disruptions to screening happened, as defined in <xref ref-type="table" rid="table1">Table 1</xref>.</p><p>The key outcome estimated in this study is the expected number of LY lost (LYL) due to disruptions in screening, defined as <inline-formula><mml:math id="inf1"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi>L</mml:mi><mml:mi>Y</mml:mi><mml:mi>L</mml:mi><mml:mo>=</mml:mo><mml:mtext> </mml:mtext><mml:mi>L</mml:mi><mml:mi>Y</mml:mi><mml:mi>N</mml:mi><mml:mi>D</mml:mi><mml:mo>−</mml:mo><mml:mi>L</mml:mi><mml:mi>Y</mml:mi></mml:mrow></mml:mstyle></mml:math></inline-formula>. The hypothetical number of LY gained (LYG) from screening under no disruptions are <inline-formula><mml:math id="inf2"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi>L</mml:mi><mml:mi>Y</mml:mi><mml:msub><mml:mi>G</mml:mi><mml:mrow><mml:mi>n</mml:mi><mml:mi>o</mml:mi><mml:mtext> </mml:mtext><mml:mi>d</mml:mi><mml:mi>i</mml:mi><mml:mi>s</mml:mi><mml:mi>r</mml:mi><mml:mi>u</mml:mi><mml:mi>p</mml:mi><mml:mi>t</mml:mi><mml:mi>i</mml:mi><mml:mi>o</mml:mi><mml:mi>n</mml:mi></mml:mrow></mml:msub><mml:mtext> </mml:mtext><mml:mo>=</mml:mo><mml:mtext> </mml:mtext><mml:mi>L</mml:mi><mml:mi>Y</mml:mi><mml:mi>N</mml:mi><mml:mi>D</mml:mi><mml:mo>−</mml:mo><mml:mi>L</mml:mi><mml:mi>Y</mml:mi><mml:mi>N</mml:mi><mml:mi>S</mml:mi></mml:mrow></mml:mstyle></mml:math></inline-formula>. Finally, we compute the percentage of life-years gained or lost due to disruption as <inline-formula><mml:math id="inf3"><mml:mi>%</mml:mi><mml:mi> </mml:mi><mml:mi>L</mml:mi><mml:mi>Y</mml:mi><mml:mi> </mml:mi><mml:mi>L</mml:mi><mml:mi>o</mml:mi><mml:mi>s</mml:mi><mml:mi>t</mml:mi><mml:mi> </mml:mi><mml:mo>=</mml:mo><mml:mn>100</mml:mn><mml:mi>*</mml:mi><mml:mi> </mml:mi><mml:mi>L</mml:mi><mml:mi>Y</mml:mi><mml:mi>L</mml:mi><mml:mi> </mml:mi><mml:mo>/</mml:mo><mml:mi> </mml:mi><mml:mi>L</mml:mi><mml:mi>Y</mml:mi><mml:msub><mml:mrow><mml:mi>G</mml:mi></mml:mrow><mml:mrow><mml:mi>n</mml:mi><mml:mi>o</mml:mi><mml:mi> </mml:mi><mml:mi>d</mml:mi><mml:mi>i</mml:mi><mml:mi>s</mml:mi><mml:mi>r</mml:mi><mml:mi>u</mml:mi><mml:mi>p</mml:mi><mml:mi>t</mml:mi><mml:mi>i</mml:mi><mml:mi>o</mml:mi><mml:mi>n</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula> . The first outcome measure (<italic>LYL</italic>) is an absolute measure of the loss of screening benefit due to pandemic disruptions. The percent LY lost due to disruptions indicates the share of screening benefit lost due to the pandemic. Following the previous analyses, we present all outcomes as LY per 1000 individuals or life days per person. We compute each of those outcomes separately for each model and report the range of outcomes observed across both models. In addition to LY outcomes, we present lifetime number of CRC cases over the remaining lifetime of individuals and number of CRC deaths (<xref ref-type="supplementary-material" rid="supp2 supp3">Supplementary files 2 and 3</xref>).</p></sec></sec><sec id="s2-4"><title>Test characteristics</title><p><xref ref-type="table" rid="table2">Table 2</xref> specifies sensitivity and specificity assumptions underlying colonoscopy and FIT exams evaluated in this study. Our main results present colonoscopy sensitivity following assumptions used in the analysis that informed the most recent USPSTF screening recommendations (<xref ref-type="bibr" rid="bib29">Zauber et al., 2008</xref>). In addition, we simulate all screening disruption scenarios under assuming lower colonoscopy sensitivity.</p><table-wrap id="table2" position="float"><label>Table 2.</label><caption><title>Per lesion test sensitivity and specificity.</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom"/><th align="left" valign="bottom" colspan="4">Sensitivity<xref ref-type="table-fn" rid="table2fn2">*</xref></th><th align="left" valign="bottom" rowspan="2">Specificity<xref ref-type="table-fn" rid="table2fn3">†</xref></th></tr><tr><th align="left" valign="bottom">Test</th><th align="left" valign="bottom">Adenoma1–5 mm</th><th align="left" valign="bottom">Adenoma6–9 mm</th><th align="left" valign="bottom">Adenoma ≥10 mm</th><th align="left" valign="bottom">Preclinical cancer</th></tr></thead><tbody><tr><td align="left" valign="bottom">Colonoscopy, high sensitivity<xref ref-type="table-fn" rid="table2fn4">‡</xref></td><td align="char" char="." valign="bottom">0.75</td><td align="char" char="." valign="bottom">0.85</td><td align="char" char="." valign="bottom">0.95</td><td align="char" char="." valign="bottom">0.95</td><td align="char" char="." valign="bottom">0.86</td></tr><tr><td align="left" valign="bottom">Colonoscopy, low sensitivity<xref ref-type="table-fn" rid="table2fn5">§</xref></td><td align="char" char="." valign="bottom">0.55</td><td align="char" char="." valign="bottom">0.70</td><td align="char" char="." valign="bottom">0.90</td><td align="char" char="." valign="bottom">0.95</td><td align="char" char="." valign="bottom">0.86</td></tr><tr><td align="left" valign="bottom" colspan="6">FIT<xref ref-type="table-fn" rid="table2fn6">¶</xref></td></tr><tr><td align="left" valign="bottom">MISCAN</td><td align="left" valign="bottom">0.00</td><td align="left" valign="bottom">0.114</td><td align="left" valign="bottom">0.159</td><td align="left" valign="bottom">0.62565/0.886</td><td align="left" valign="bottom">0.97</td></tr><tr><td align="left" valign="bottom">CRC-SPIN</td><td align="left" valign="bottom">0.05</td><td align="left" valign="bottom">0.15</td><td align="left" valign="bottom">0.22</td><td align="left" valign="bottom"><xref ref-type="table-fn" rid="table2fn2">*</xref>0.74</td><td align="left" valign="bottom">0.97</td></tr></tbody></table><table-wrap-foot><fn><p>Notes: This table presents the assumed test characteristics. We simulated two colonoscopy sensitivity scenarios seeking to represent a range of colonoscopy sensitivity of gastroenterologists in the United States.</p></fn><fn id="table2fn2"><label>*</label><p>Sensitivity is for lesions within reach of the scope. We assume the same test characteristics for follow-up and surveillance colonoscopy as for screening colonoscopy.</p></fn><fn id="table2fn3"><label>†</label><p>For FIT, the lack of specificity reflects detection of bleeding from other causes. We assume other-cause bleeding is independent of adenoma status. For colonoscopy, the lack of specificity reflects detection of non-adenomatous lesions, but specificity is handled in post-processing in cost-effectiveness analyses. Since this study does not consider burden outcomes, specificity is not considered in this paper. Specificity values were obtained from <xref ref-type="bibr" rid="bib14">Lin et al., 2021</xref>.</p></fn><fn id="table2fn4"><label>‡</label><p>Baseline scenarios used in <xref ref-type="bibr" rid="bib29">Zauber et al., 2008</xref>.</p></fn><fn id="table2fn5"><label>§</label><p>In line with low-sensitivity scenarios compatible with <xref ref-type="bibr" rid="bib22">Rutter et al., 2022</xref>.</p></fn><fn id="table2fn6"><label>¶</label><p>CRC-SPIN uses per-person test sensitivity for stool-based tests that are based on the size of the most advanced lesion. To account for the likelihood that a person with multiple adenomas is more likely than a person with only one to have a positive stool test, MISCAN uses lesion-based sensitivities instead of person-based sensitivities. Lesion-based sensitivities were derived by calibrating the person-based sensitivities to the number of people having one or more small/medium/large adenomas or cancers detected by stool-based testing with diagnostic colonoscopy, divided by those having one or more small/medium/large adenomas or cancers detected by colonoscopy screening.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s2-5"><title>CRC surveillance</title><p>We assume that individuals with an adenoma detected undergo colonoscopic surveillance according to the Multi-Society Task Force (MSTF) guidelines. These guidelines provide intervals for surveillance based on baseline findings and findings at the first surveillance colonoscopy. We assume that the intervals provided can be more generally expressed as the intervals based on the most recent colonoscopy (‘first-most recent colonoscopy’) and the colonoscopy prior to that (‘second-most recent colonoscopy’). In situations where the MSTF provided a range rather than a single interval, we assumed that the shortest interval would be used in routine practice. The resulting intervals are shown in <xref ref-type="table" rid="table3">Table 3</xref>.</p><table-wrap id="table3" position="float"><label>Table 3.</label><caption><title>CRC surveillance intervals.</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Finding at second-most recent colonoscopy<xref ref-type="table-fn" rid="table3fn1"><sup>*</sup></xref><xref ref-type="table-fn" rid="table3fn2"><sup>†</sup></xref></th><th align="left" valign="bottom">Finding at first-most recent colonoscopy<xref ref-type="table-fn" rid="table3fn1"><sup>*</sup></xref><xref ref-type="table-fn" rid="table3fn2"><sup>†</sup></xref></th><th align="left" valign="bottom">Interval<xref ref-type="table-fn" rid="table3fn3"><sup>‡</sup></xref> to next colonoscopy, years</th></tr></thead><tbody><tr><td align="left" valign="bottom">No prior colonoscopy</td><td align="left" valign="bottom">Normal colonoscopy</td><td align="left" valign="bottom">See note below<xref ref-type="table-fn" rid="table3fn4">§</xref></td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom">1–2 adenomas &lt;10 mm</td><td align="char" char="." valign="bottom">7</td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom">3–4 adenomas &lt;10 mm</td><td align="char" char="." valign="bottom">3</td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom">10 adenomas &lt;10 mm or any adenoma ≥10 mm</td><td align="char" char="." valign="bottom">3</td></tr><tr><td align="left" valign="bottom"/><td align="char" char="." valign="bottom">&gt;10 adenomas</td><td align="char" char="." valign="bottom">1</td></tr><tr><td align="left" valign="bottom">Normal colonoscopy</td><td align="left" valign="bottom">Normal colonoscopy</td><td align="char" char="." valign="bottom">10</td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom">1–2 adenomas &lt;10 mm</td><td align="char" char="." valign="bottom">7</td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom">3–4 adenomas &lt;10 mm</td><td align="char" char="." valign="bottom">3</td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom">5–10 adenomas &lt;10 mm or any adenoma ≥10 mm</td><td align="char" char="." valign="bottom">3</td></tr><tr><td align="left" valign="bottom"/><td align="char" char="." valign="bottom">&gt;10 adenomas</td><td align="char" char="." valign="bottom">1</td></tr><tr><td align="left" valign="bottom">1–2 adenomas &lt;10 mm</td><td align="left" valign="bottom">Normal colonoscopy</td><td align="char" char="." valign="bottom">10</td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom">1–2 adenomas &lt;10 mm</td><td align="char" char="." valign="bottom">7</td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom">3–4 adenomas &lt;10 mm</td><td align="char" char="." valign="bottom">3</td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom">5–10 adenomas &lt;10 mm or any adenoma ≥10 mm</td><td align="char" char="." valign="bottom">3</td></tr><tr><td align="left" valign="bottom"/><td align="char" char="." valign="bottom">&gt;10 adenomas</td><td align="char" char="." valign="bottom">1</td></tr><tr><td align="left" valign="bottom">3–4 adenomas &lt;10 mm</td><td align="left" valign="bottom">Normal colonoscopy</td><td align="char" char="." valign="bottom">10</td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom">1–2 adenomas &lt;10 mm</td><td align="char" char="." valign="bottom">7</td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom">3–4 adenomas &lt;10 mm</td><td align="char" char="." valign="bottom">3</td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom">5–10 adenomas &lt;10 mm or any adenoma ≥10 mm</td><td align="char" char="." valign="bottom">3</td></tr><tr><td align="left" valign="bottom"/><td align="char" char="." valign="bottom">&gt;10 adenomas</td><td align="char" char="." valign="bottom">1</td></tr><tr><td align="left" valign="bottom">5–10 adenomas &lt;10 mm</td><td align="left" valign="bottom">Normal colonoscopy</td><td align="char" char="." valign="bottom">5</td></tr><tr><td align="left" valign="bottom">or</td><td align="left" valign="bottom">1–2 adenomas &lt;10 mm</td><td align="char" char="." valign="bottom">5</td></tr><tr><td align="left" valign="bottom">any adenoma ≥10 mm</td><td align="left" valign="bottom">3–4 adenomas &lt;10 mm</td><td align="char" char="." valign="bottom">3</td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom">5–10 adenomas &lt;10 mm or any adenoma ≥10 mm</td><td align="char" char="." valign="bottom">3</td></tr><tr><td align="left" valign="bottom"/><td align="char" char="." valign="bottom">&gt;10 adenomas</td><td align="char" char="." valign="bottom">1</td></tr><tr><td align="left" valign="bottom">&gt;10 adenomas of any size</td><td align="left" valign="bottom">Normal colonoscopy</td><td align="char" char="." valign="bottom">5</td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom">1–2 adenomas &lt;10 mm</td><td align="char" char="." valign="bottom">5</td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom">3–4 adenomas &lt;10 mm</td><td align="char" char="." valign="bottom">3</td></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom">5–10 adenomas &lt;10 mm or any adenoma ≥10 mm</td><td align="char" char="." valign="bottom">3</td></tr><tr><td align="left" valign="bottom"/><td align="char" char="." valign="bottom">&gt;10 adenomas</td><td align="char" char="." valign="bottom">1</td></tr></tbody></table><table-wrap-foot><fn id="table3fn1"><label>*</label><p>A normal colonoscopy is one in which no adenomas, SSPs (not currently simulated), or CRC is detected.</p></fn><fn id="table3fn2"><label>†</label><p>This table omits the case where CRC is detected at a screening, diagnostic, or surveillance colonoscopy because the CISNET CRC models do not simulate detailed events following CRC diagnosis.</p></fn><fn id="table3fn3"><label>‡</label><p>The Multi-Society Task Force provides a range for some intervals (e.g. the interval for 3–4 adenomas &lt;10 mm is 3–5 years). In such cases, we selected the shortest intervals provided.</p></fn><fn id="table3fn4"><label>§</label><p>A person whose first screening or diagnostic colonoscopy is normal does not enter surveillance but instead resumes screening with the original modality 10 years after the normal colonoscopy. The exception to the 10-year waiting period is when the first colonoscopy is a screening colonoscopy with an <italic>x</italic>-year interval, where <italic>x</italic>&gt;10. In that case, the next colonoscopy is in <italic>x</italic> years.</p></fn></table-wrap-foot></table-wrap><p>We assume that persons in whom adenoma(s) have been detected remain on surveillance until age 85, provided that no adenomas are detected at the last surveillance colonoscopy. If adenomas are detected, then surveillance continues according to the clinical findings at the last colonoscopy until the person has a colonoscopy with no adenomas detected. For example, if a person has a surveillance colonoscopy at age 83 and no adenomas are detected at this exam or the exam before this one, they would be recommended to have their next surveillance at age 93. Age 93 is after the surveillance stopping age of 85 and the exam prior to age 85 was negative, so they will not have any more surveillance colonoscopies after age 83. However, if the exam at age 83 instead detected 1–2 small adenomas, they would come back for their surveillance colonoscopy at age 90, because adenomas were detected at the exam at age 83.</p></sec></sec><sec id="s3" sec-type="results"><title>Results</title><p>Loss of life due to screening disruptions was the largest for cohorts with severe disruptions after the pandemic (<xref ref-type="fig" rid="fig1">Figure 1</xref>). Aside from not receiving any screening, the worst-case scenario for the 50-year-old cohort was to postpone screening until age 65 when they become Medicare eligible. This cohort (scenario U50 | C@65) is expected to lose 104–127 LY per 1000 individuals – a 38–42% loss in LYG compared to a no-disruption scenario where they start screening at age 50 (<xref ref-type="table" rid="table4">Table 4</xref>). This cohort would be 1.3–1.9 times more likely to have CRC over their lifetime (<xref ref-type="supplementary-material" rid="supp2">Supplementary file 2</xref>) and 1.6–2.0 times more likely to die with CRC (<xref ref-type="supplementary-material" rid="supp3">Supplementary file 3</xref>) compared to a cohort that started screening at age 50. Other disruption scenarios are predicted to have minor effects on this cohort. For example, 50-year-olds with colonoscopy screening delayed by 18 months (scenario U50 | C18m) are expected to experience a loss of 6–7 LY per 1000 individuals, and a 2% loss in LYG from screening compared to a no-disruption scenario.</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>Screening benefits lost due to disruptions by cohort and scenario.</title><p>Notes<italic>:</italic> Each dot represents the estimated life-years lost per 1000 individuals or life-days lost from one model under the high sensitivity scenario. Results are ordered from highest to lowest reduction in benefit induced by the pandemic. Scenarios that result in less than 2 life-days lost per person are omitted from this figure and presented in a Supplementary figure. This figure does not present a counterfactual no-screening scenario for the 50-year-olds.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-85264-fig1-v1.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 1.</label><caption><title>Estimated loss of life in minor disruption scenarios.</title><p>Notes: Each dot represents the estimated life-years lost per 1000 individuals or life-days lost from one model under the high sensitivity scenario. Results are ordered from highest to lowest reduction in benefit induced by the pandemic. This figure supplement only shows scenarios that resulted in in less than 2 life-days lost per person. This figure does not present a counterfactual no-screening scenario for the 50-year-olds.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-85264-fig1-figsupp1-v1.tif"/></fig></fig-group><table-wrap id="table4" position="float"><label>Table 4.</label><caption><title>Projected life-years (LY) per 1000 individuals.</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="top" rowspan="2">Scenario</th><th align="left" valign="top" rowspan="2">Model</th><th align="left" valign="top">No screening</th><th align="left" valign="top" colspan="2">Screening without disruptions</th><th align="left" valign="top" colspan="2">Screening with disruptions</th><th align="left" valign="top" colspan="2">Loss due to disruptions</th></tr><tr><th align="left" valign="top">LY[a]</th><th align="left" valign="top">LY[b]</th><th align="left" valign="top">LYG[b-a]</th><th align="left" valign="top">LY[c]</th><th align="left" valign="top">LYG[c-a]</th><th align="left" valign="top">LY[b-c]</th><th align="left" valign="top">% LYG loss[(b-c)/b]</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="2">U50 | C3m</td><td align="left" valign="top">CRCSPIN</td><td align="char" char="." valign="top">31,595</td><td align="char" char="." valign="top">31,893</td><td align="char" char="." valign="top">299</td><td align="char" char="." valign="top">31,892</td><td align="char" char="." valign="top">297</td><td align="char" char="." valign="top">2</td><td align="char" char="." valign="top">1</td></tr><tr><td align="left" valign="top">MISCAN</td><td align="char" char="." valign="top">31,222</td><td align="char" char="." valign="top">31,494</td><td align="char" char="." valign="top">273</td><td align="char" char="." valign="top">31,491</td><td align="char" char="." valign="top">270</td><td align="char" char="." valign="top">3</td><td align="char" char="." valign="top">1</td></tr><tr><td align="left" valign="top" rowspan="2">U50 | C9m</td><td align="left" valign="top">CRCSPIN</td><td align="char" char="." valign="top">31,595</td><td align="char" char="." valign="top">31,893</td><td align="char" char="." valign="top">299</td><td align="char" char="." valign="top">31,890</td><td align="char" char="." valign="top">295</td><td align="char" char="." valign="top">3</td><td align="char" char="." valign="top">1</td></tr><tr><td align="left" valign="top">MISCAN</td><td align="char" char="." valign="top">31,222</td><td align="char" char="." valign="top">31,494</td><td align="char" char="." valign="top">273</td><td align="char" char="." valign="top">31,490</td><td align="char" char="." valign="top">268</td><td align="char" char="." valign="top">5</td><td align="char" char="." valign="top">2</td></tr><tr><td align="left" valign="top" rowspan="2">U50 | C18m</td><td align="left" valign="top">CRCSPIN</td><td align="char" char="." valign="top">31,595</td><td align="char" char="." valign="top">31,893</td><td align="char" char="." valign="top">299</td><td align="char" char="." valign="top">31,886</td><td align="char" char="." valign="top">291</td><td align="char" char="." valign="top">7</td><td align="char" char="." valign="top">2</td></tr><tr><td align="left" valign="top">MISCAN</td><td align="char" char="." valign="top">31,222</td><td align="char" char="." valign="top">31,494</td><td align="char" char="." valign="top">273</td><td align="char" char="." valign="top">31,488</td><td align="char" char="." valign="top">266</td><td align="char" char="." valign="top">6</td><td align="char" char="." valign="top">2</td></tr><tr><td align="left" valign="top" rowspan="2">U50 | C@65</td><td align="left" valign="top">CRCSPIN</td><td align="char" char="." valign="top">31,595</td><td align="char" char="." valign="top">31,893</td><td align="char" char="." valign="top">299</td><td align="char" char="." valign="top">31,766</td><td align="char" char="." valign="top">172</td><td align="char" char="." valign="top">127</td><td align="char" char="." valign="top">43</td></tr><tr><td align="left" valign="top">MISCAN</td><td align="char" char="." valign="top">31,222</td><td align="char" char="." valign="top">31,494</td><td align="char" char="." valign="top">273</td><td align="char" char="." valign="top">31,390</td><td align="char" char="." valign="top">169</td><td align="char" char="." valign="top">104</td><td align="char" char="." valign="top">38</td></tr><tr><td align="left" valign="top" rowspan="2">U50 | F3m</td><td align="left" valign="top">CRCSPIN</td><td align="char" char="." valign="top">31,595</td><td align="char" char="." valign="top">31,866</td><td align="char" char="." valign="top">271</td><td align="char" char="." valign="top">31,865</td><td align="char" char="." valign="top">270</td><td align="char" char="." valign="top">1</td><td align="char" char="." valign="top">0</td></tr><tr><td align="left" valign="top">MISCAN</td><td align="char" char="." valign="top">31,222</td><td align="char" char="." valign="top">31,483</td><td align="char" char="." valign="top">261</td><td align="char" char="." valign="top">31,481</td><td align="char" char="." valign="top">259</td><td align="char" char="." valign="top">1</td><td align="char" char="." valign="top">1</td></tr><tr><td align="left" valign="top" rowspan="2">U50 | F9m</td><td align="left" valign="top">CRCSPIN</td><td align="char" char="." valign="top">31,595</td><td align="char" char="." valign="top">31,866</td><td align="char" char="." valign="top">271</td><td align="char" char="." valign="top">31,862</td><td align="char" char="." valign="top">268</td><td align="char" char="." valign="top">3</td><td align="char" char="." valign="top">1</td></tr><tr><td align="left" valign="top">MISCAN</td><td align="char" char="." valign="top">31,222</td><td align="char" char="." valign="top">31,483</td><td align="char" char="." valign="top">261</td><td align="char" char="." valign="top">31,480</td><td align="char" char="." valign="top">258</td><td align="char" char="." valign="top">2</td><td align="char" char="." valign="top">1</td></tr><tr><td align="left" valign="top" rowspan="2">U50 | F18m</td><td align="left" valign="top">CRCSPIN</td><td align="char" char="." valign="top">31,595</td><td align="char" char="." valign="top">31,866</td><td align="char" char="." valign="top">271</td><td align="char" char="." valign="top">31,858</td><td align="char" char="." valign="top">264</td><td align="char" char="." valign="top">7</td><td align="char" char="." valign="top">3</td></tr><tr><td align="left" valign="top">MISCAN</td><td align="char" char="." valign="top">31,222</td><td align="char" char="." valign="top">31,483</td><td align="char" char="." valign="top">261</td><td align="char" char="." valign="top">31,478</td><td align="char" char="." valign="top">256</td><td align="char" char="." valign="top">5</td><td align="char" char="." valign="top">2</td></tr><tr><td align="left" valign="top" rowspan="2">U60 | C3m</td><td align="left" valign="top">CRCSPIN</td><td align="char" char="." valign="top">23,336</td><td align="char" char="." valign="top">23,557</td><td align="char" char="." valign="top">221</td><td align="char" char="." valign="top">23,560</td><td align="char" char="." valign="top">224</td><td align="char" char="." valign="top">-3</td><td align="char" char="." valign="top">-1</td></tr><tr><td align="left" valign="top">MISCAN</td><td align="char" char="." valign="top">23,114</td><td align="char" char="." valign="top">23,309</td><td align="char" char="." valign="top">195</td><td align="char" char="." valign="top">23,304</td><td align="char" char="." valign="top">190</td><td align="char" char="." valign="top">5</td><td align="char" char="." valign="top">3</td></tr><tr><td align="left" valign="top" rowspan="2">U60 | C9m</td><td align="left" valign="top">CRCSPIN</td><td align="char" char="." valign="top">23,336</td><td align="char" char="." valign="top">23,557</td><td align="char" char="." valign="top">221</td><td align="char" char="." valign="top">23,555</td><td align="char" char="." valign="top">219</td><td align="char" char="." valign="top">2</td><td align="char" char="." valign="top">1</td></tr><tr><td align="left" valign="top">MISCAN</td><td align="char" char="." valign="top">23,114</td><td align="char" char="." valign="top">23,309</td><td align="char" char="." valign="top">195</td><td align="char" char="." valign="top">23,301</td><td align="char" char="." valign="top">187</td><td align="char" char="." valign="top">8</td><td align="char" char="." valign="top">4</td></tr><tr><td align="left" valign="top" rowspan="2">U60 | C18m</td><td align="left" valign="top">CRCSPIN</td><td align="char" char="." valign="top">23,336</td><td align="char" char="." valign="top">23,557</td><td align="char" char="." valign="top">221</td><td align="char" char="." valign="top">23,547</td><td align="char" char="." valign="top">211</td><td align="char" char="." valign="top">10</td><td align="char" char="." valign="top">4</td></tr><tr><td align="left" valign="top">MISCAN</td><td align="char" char="." valign="top">23,114</td><td align="char" char="." valign="top">23,309</td><td align="char" char="." valign="top">195</td><td align="char" char="." valign="top">23,296</td><td align="char" char="." valign="top">182</td><td align="char" char="." valign="top">14</td><td align="char" char="." valign="top">7</td></tr><tr><td align="left" valign="top" rowspan="2">U60 | C@65</td><td align="left" valign="top">CRCSPIN</td><td align="char" char="." valign="top">23,336</td><td align="char" char="." valign="top">23,557</td><td align="char" char="." valign="top">221</td><td align="char" char="." valign="top">23,512</td><td align="char" char="." valign="top">176</td><td align="char" char="." valign="top">45</td><td align="char" char="." valign="top">20</td></tr><tr><td align="left" valign="top">MISCAN</td><td align="char" char="." valign="top">23,114</td><td align="char" char="." valign="top">23,309</td><td align="char" char="." valign="top">195</td><td align="char" char="." valign="top">23,267</td><td align="char" char="." valign="top">153</td><td align="char" char="." valign="top">42</td><td align="char" char="." valign="top">21</td></tr><tr><td align="left" valign="top" rowspan="2">U60 | F3m</td><td align="left" valign="top">CRCSPIN</td><td align="char" char="." valign="top">23,336</td><td align="char" char="." valign="top">23,528</td><td align="char" char="." valign="top">191</td><td align="char" char="." valign="top">23,529</td><td align="char" char="." valign="top">193</td><td align="char" char="." valign="top">-2</td><td align="char" char="." valign="top">-1</td></tr><tr><td align="left" valign="top">MISCAN</td><td align="char" char="." valign="top">23,114</td><td align="char" char="." valign="top">23,291</td><td align="char" char="." valign="top">177</td><td align="char" char="." valign="top">23,288</td><td align="char" char="." valign="top">174</td><td align="char" char="." valign="top">3</td><td align="char" char="." valign="top">1</td></tr><tr><td align="left" valign="top" rowspan="2">U60 | F9m</td><td align="left" valign="top">CRCSPIN</td><td align="char" char="." valign="top">23,336</td><td align="char" char="." valign="top">23,528</td><td align="char" char="." valign="top">191</td><td align="char" char="." valign="top">23,525</td><td align="char" char="." valign="top">189</td><td align="char" char="." valign="top">2</td><td align="char" char="." valign="top">1</td></tr><tr><td align="left" valign="top">MISCAN</td><td align="char" char="." valign="top">23,114</td><td align="char" char="." valign="top">23,291</td><td align="char" char="." valign="top">177</td><td align="char" char="." valign="top">23,285</td><td align="char" char="." valign="top">171</td><td align="char" char="." valign="top">6</td><td align="char" char="." valign="top">3</td></tr><tr><td align="left" valign="top" rowspan="2">U60 | F18m</td><td align="left" valign="top">CRCSPIN</td><td align="char" char="." valign="top">23,336</td><td align="char" char="." valign="top">23,528</td><td align="char" char="." valign="top">191</td><td align="char" char="." valign="top">23,519</td><td align="char" char="." valign="top">183</td><td align="char" char="." valign="top">8</td><td align="char" char="." valign="top">4</td></tr><tr><td align="left" valign="top">MISCAN</td><td align="char" char="." valign="top">23,114</td><td align="char" char="." valign="top">23,291</td><td align="char" char="." valign="top">177</td><td align="char" char="." valign="top">23,280</td><td align="char" char="." valign="top">166</td><td align="char" char="." valign="top">11</td><td align="char" char="." valign="top">6</td></tr><tr><td align="left" valign="top" rowspan="2">C60 | C3m</td><td align="left" valign="top">CRCSPIN</td><td align="char" char="." valign="top">23,243</td><td align="char" char="." valign="top">23,541</td><td align="char" char="." valign="top">298</td><td align="char" char="." valign="top">23,541</td><td align="char" char="." valign="top">299</td><td align="char" char="." valign="top">0</td><td align="char" char="." valign="top">0</td></tr><tr><td align="left" valign="top">MISCAN</td><td align="char" char="." valign="top">23,077</td><td align="char" char="." valign="top">23,320</td><td align="char" char="." valign="top">243</td><td align="char" char="." valign="top">23,318</td><td align="char" char="." valign="top">241</td><td align="char" char="." valign="top">2</td><td align="char" char="." valign="top">1</td></tr><tr><td align="left" valign="top" rowspan="2">C60 | C9m</td><td align="left" valign="top">CRCSPIN</td><td align="char" char="." valign="top">23,242</td><td align="char" char="." valign="top">23,541</td><td align="char" char="." valign="top">298</td><td align="char" char="." valign="top">23,541</td><td align="char" char="." valign="top">299</td><td align="char" char="." valign="top">0</td><td align="char" char="." valign="top">0</td></tr><tr><td align="left" valign="top">MISCAN</td><td align="char" char="." valign="top">23,077</td><td align="char" char="." valign="top">23,319</td><td align="char" char="." valign="top">243</td><td align="char" char="." valign="top">23,317</td><td align="char" char="." valign="top">240</td><td align="char" char="." valign="top">2</td><td align="char" char="." valign="top">1</td></tr><tr><td align="left" valign="top" rowspan="2">C60 | C18m</td><td align="left" valign="top">CRCSPIN</td><td align="char" char="." valign="top">23,242</td><td align="char" char="." valign="top">23,541</td><td align="char" char="." valign="top">298</td><td align="char" char="." valign="top">23,540</td><td align="char" char="." valign="top">298</td><td align="char" char="." valign="top">0</td><td align="char" char="." valign="top">0</td></tr><tr><td align="left" valign="top">MISCAN</td><td align="char" char="." valign="top">23,077</td><td align="char" char="." valign="top">23,320</td><td align="char" char="." valign="top">243</td><td align="char" char="." valign="top">23,317</td><td align="char" char="." valign="top">239</td><td align="char" char="." valign="top">3</td><td align="char" char="." valign="top">1</td></tr><tr><td align="left" valign="top" rowspan="2">C60 | F3m</td><td align="left" valign="top">CRCSPIN</td><td align="char" char="." valign="top">23,242</td><td align="char" char="." valign="top">23,541</td><td align="char" char="." valign="top">298</td><td align="char" char="." valign="top">23,532</td><td align="char" char="." valign="top">289</td><td align="char" char="." valign="top">9</td><td align="char" char="." valign="top">3</td></tr><tr><td align="left" valign="top">MISCAN</td><td align="char" char="." valign="top">23,077</td><td align="char" char="." valign="top">23,320</td><td align="char" char="." valign="top">243</td><td align="char" char="." valign="top">23,310</td><td align="char" char="." valign="top">233</td><td align="char" char="." valign="top">10</td><td align="char" char="." valign="top">4</td></tr><tr><td align="left" valign="top" rowspan="2">C60 | F9m</td><td align="left" valign="top">CRCSPIN</td><td align="char" char="." valign="top">23,243</td><td align="char" char="." valign="top">23,541</td><td align="char" char="." valign="top">298</td><td align="char" char="." valign="top">23,532</td><td align="char" char="." valign="top">289</td><td align="char" char="." valign="top">9</td><td align="char" char="." valign="top">3</td></tr><tr><td align="left" valign="top">MISCAN</td><td align="char" char="." valign="top">23,077</td><td align="char" char="." valign="top">23,319</td><td align="char" char="." valign="top">243</td><td align="char" char="." valign="top">23,310</td><td align="char" char="." valign="top">233</td><td align="char" char="." valign="top">9</td><td align="char" char="." valign="top">4</td></tr><tr><td align="left" valign="top" rowspan="2">C60 | F18m</td><td align="left" valign="top">CRCSPIN</td><td align="char" char="." valign="top">23,243</td><td align="char" char="." valign="top">23,541</td><td align="char" char="." valign="top">298</td><td align="char" char="." valign="top">23,532</td><td align="char" char="." valign="top">289</td><td align="char" char="." valign="top">9</td><td align="char" char="." valign="top">3</td></tr><tr><td align="left" valign="top">MISCAN</td><td align="char" char="." valign="top">23,077</td><td align="char" char="." valign="top">23,320</td><td align="char" char="." valign="top">243</td><td align="char" char="." valign="top">23,309</td><td align="char" char="." valign="top">232</td><td align="char" char="." valign="top">11</td><td align="char" char="." valign="top">4</td></tr><tr><td align="left" valign="top" rowspan="2">C60 | C@65</td><td align="left" valign="top">CRCSPIN</td><td align="char" char="." valign="top">23,243</td><td align="char" char="." valign="top">23,541</td><td align="char" char="." valign="top">298</td><td align="char" char="." valign="top">23,538</td><td align="char" char="." valign="top">295</td><td align="char" char="." valign="top">3</td><td align="char" char="." valign="top">1</td></tr><tr><td align="left" valign="top">MISCAN</td><td align="char" char="." valign="top">23,077</td><td align="char" char="." valign="top">23,320</td><td align="char" char="." valign="top">243</td><td align="char" char="." valign="top">23,308</td><td align="char" char="." valign="top">231</td><td align="char" char="." valign="top">11</td><td align="char" char="." valign="top">5</td></tr><tr><td align="left" valign="top" rowspan="2">C60 | U</td><td align="left" valign="top">CRCSPIN</td><td align="char" char="." valign="top">23,243</td><td align="char" char="." valign="top">23,541</td><td align="char" char="." valign="top">298</td><td align="char" char="." valign="top">23,435</td><td align="char" char="." valign="top">192</td><td align="char" char="." valign="top">106</td><td align="char" char="." valign="top">36</td></tr><tr><td align="left" valign="top">MISCAN</td><td align="char" char="." valign="top">23,077</td><td align="char" char="." valign="top">23,320</td><td align="char" char="." valign="top">243</td><td align="char" char="." valign="top">23,195</td><td align="char" char="." valign="top">118</td><td align="char" char="." valign="top">125</td><td align="char" char="." valign="top">51</td></tr><tr><td align="left" valign="top" rowspan="2">F60 | F3m</td><td align="left" valign="top">CRCSPIN</td><td align="char" char="." valign="top">23,307</td><td align="char" char="." valign="top">23,579</td><td align="char" char="." valign="top">272</td><td align="char" char="." valign="top">23,576</td><td align="char" char="." valign="top">269</td><td align="char" char="." valign="top">3</td><td align="char" char="." valign="top">1</td></tr><tr><td align="left" valign="top">MISCAN</td><td align="char" char="." valign="top">23,144</td><td align="char" char="." valign="top">23,377</td><td align="char" char="." valign="top">234</td><td align="char" char="." valign="top">23,377</td><td align="char" char="." valign="top">233</td><td align="char" char="." valign="top">0</td><td align="char" char="." valign="top">0</td></tr><tr><td align="left" valign="top" rowspan="2">F60 | F9m</td><td align="left" valign="top">CRCSPIN</td><td align="char" char="." valign="top">23,306</td><td align="char" char="." valign="top">23,578</td><td align="char" char="." valign="top">272</td><td align="char" char="." valign="top">23,575</td><td align="char" char="." valign="top">269</td><td align="char" char="." valign="top">3</td><td align="char" char="." valign="top">1</td></tr><tr><td align="left" valign="top">MISCAN</td><td align="char" char="." valign="top">23,143</td><td align="char" char="." valign="top">23,376</td><td align="char" char="." valign="top">234</td><td align="char" char="." valign="top">23,376</td><td align="char" char="." valign="top">234</td><td align="char" char="." valign="top">0</td><td align="char" char="." valign="top">0</td></tr><tr><td align="left" valign="top" rowspan="2">F60 | F18m</td><td align="left" valign="top">CRCSPIN</td><td align="char" char="." valign="top">23,307</td><td align="char" char="." valign="top">23,578</td><td align="char" char="." valign="top">272</td><td align="char" char="." valign="top">23,573</td><td align="char" char="." valign="top">267</td><td align="char" char="." valign="top">5</td><td align="char" char="." valign="top">2</td></tr><tr><td align="left" valign="top">MISCAN</td><td align="char" char="." valign="top">23,143</td><td align="char" char="." valign="top">23,377</td><td align="char" char="." valign="top">234</td><td align="char" char="." valign="top">23,376</td><td align="char" char="." valign="top">233</td><td align="char" char="." valign="top">1</td><td align="char" char="." valign="top">0</td></tr><tr><td align="left" valign="top" rowspan="2">F60 | U</td><td align="left" valign="top">CRCSPIN</td><td align="char" char="." valign="top">23,307</td><td align="char" char="." valign="top">23,579</td><td align="char" char="." valign="top">272</td><td align="char" char="." valign="top">23,467</td><td align="char" char="." valign="top">160</td><td align="char" char="." valign="top">111</td><td align="char" char="." valign="top">41</td></tr><tr><td align="left" valign="top">MISCAN</td><td align="char" char="." valign="top">23,143</td><td align="char" char="." valign="top">23,376</td><td align="char" char="." valign="top">234</td><td align="char" char="." valign="top">23,283</td><td align="char" char="." valign="top">141</td><td align="char" char="." valign="top">93</td><td align="char" char="." valign="top">40</td></tr><tr><td align="left" valign="top" rowspan="2">f60 | F3m</td><td align="left" valign="top">CRCSPIN</td><td align="char" char="." valign="top">23,314</td><td align="char" char="." valign="top">23,562</td><td align="char" char="." valign="top">249</td><td align="char" char="." valign="top">23,560</td><td align="char" char="." valign="top">247</td><td align="char" char="." valign="top">2</td><td align="char" char="." valign="top">1</td></tr><tr><td align="left" valign="top">MISCAN</td><td align="char" char="." valign="top">23,136</td><td align="char" char="." valign="top">23,355</td><td align="char" char="." valign="top">219</td><td align="char" char="." valign="top">23,353</td><td align="char" char="." valign="top">217</td><td align="char" char="." valign="top">2</td><td align="char" char="." valign="top">1</td></tr><tr><td align="left" valign="top" rowspan="2">f60 | F9m</td><td align="left" valign="top">CRCSPIN</td><td align="char" char="." valign="top">23,314</td><td align="char" char="." valign="top">23,563</td><td align="char" char="." valign="top">249</td><td align="char" char="." valign="top">23,559</td><td align="char" char="." valign="top">245</td><td align="char" char="." valign="top">4</td><td align="char" char="." valign="top">1</td></tr><tr><td align="left" valign="top">MISCAN</td><td align="char" char="." valign="top">23,136</td><td align="char" char="." valign="top">23,355</td><td align="char" char="." valign="top">219</td><td align="char" char="." valign="top">23,352</td><td align="char" char="." valign="top">216</td><td align="char" char="." valign="top">3</td><td align="char" char="." valign="top">1</td></tr><tr><td align="left" valign="top" rowspan="2">f60 | F18m</td><td align="left" valign="top">CRCSPIN</td><td align="char" char="." valign="top">23,313</td><td align="char" char="." valign="top">23,562</td><td align="char" char="." valign="top">249</td><td align="char" char="." valign="top">23,556</td><td align="char" char="." valign="top">242</td><td align="char" char="." valign="top">6</td><td align="char" char="." valign="top">3</td></tr><tr><td align="left" valign="top">MISCAN</td><td align="char" char="." valign="top">23,136</td><td align="char" char="." valign="top">23,355</td><td align="char" char="." valign="top">219</td><td align="char" char="." valign="top">23,350</td><td align="char" char="." valign="top">214</td><td align="char" char="." valign="top">5</td><td align="char" char="." valign="top">2</td></tr><tr><td align="left" valign="top" rowspan="2">f60 | U</td><td align="left" valign="top">CRCSPIN</td><td align="char" char="." valign="top">23,313</td><td align="char" char="." valign="top">23,562</td><td align="char" char="." valign="top">249</td><td align="char" char="." valign="top">23,419</td><td align="char" char="." valign="top">105</td><td align="char" char="." valign="top">143</td><td align="char" char="." valign="top">58</td></tr><tr><td align="left" valign="top">MISCAN</td><td align="char" char="." valign="top">23,134</td><td align="char" char="." valign="top">23,353</td><td align="char" char="." valign="top">219</td><td align="char" char="." valign="top">23,203</td><td align="char" char="." valign="top">68</td><td align="char" char="." valign="top">150</td><td align="char" char="." valign="top">69</td></tr><tr><td align="left" valign="top" rowspan="2">U70 | C3m</td><td align="left" valign="top">CRCSPIN</td><td align="char" char="." valign="top">15,973</td><td align="char" char="." valign="top">16,102</td><td align="char" char="." valign="top">128</td><td align="char" char="." valign="top">16,099</td><td align="char" char="." valign="top">126</td><td align="char" char="." valign="top">3</td><td align="char" char="." valign="top">2</td></tr><tr><td align="left" valign="top">MISCAN</td><td align="char" char="." valign="top">15,748</td><td align="char" char="." valign="top">15,866</td><td align="char" char="." valign="top">117</td><td align="char" char="." valign="top">15,857</td><td align="char" char="." valign="top">108</td><td align="char" char="." valign="top">9</td><td align="char" char="." valign="top">8</td></tr><tr><td align="left" valign="top" rowspan="2">U70 | C9m</td><td align="left" valign="top">CRCSPIN</td><td align="char" char="." valign="top">15,973</td><td align="char" char="." valign="top">16,102</td><td align="char" char="." valign="top">128</td><td align="char" char="." valign="top">16,094</td><td align="char" char="." valign="top">120</td><td align="char" char="." valign="top">8</td><td align="char" char="." valign="top">6</td></tr><tr><td align="left" valign="top">MISCAN</td><td align="char" char="." valign="top">15,748</td><td align="char" char="." valign="top">15,866</td><td align="char" char="." valign="top">117</td><td align="char" char="." valign="top">15,852</td><td align="char" char="." valign="top">103</td><td align="char" char="." valign="top">14</td><td align="char" char="." valign="top">12</td></tr><tr><td align="left" valign="top" rowspan="2">U70 | C18m</td><td align="left" valign="top">CRCSPIN</td><td align="char" char="." valign="top">15,973</td><td align="char" char="." valign="top">16,102</td><td align="char" char="." valign="top">128</td><td align="char" char="." valign="top">16,086</td><td align="char" char="." valign="top">113</td><td align="char" char="." valign="top">16</td><td align="char" char="." valign="top">12</td></tr><tr><td align="left" valign="top">MISCAN</td><td align="char" char="." valign="top">15,748</td><td align="char" char="." valign="top">15,866</td><td align="char" char="." valign="top">117</td><td align="char" char="." valign="top">15,845</td><td align="char" char="." valign="top">97</td><td align="char" char="." valign="top">21</td><td align="char" char="." valign="top">18</td></tr><tr><td align="left" valign="top" rowspan="2">U70 | C@75</td><td align="left" valign="top">CRCSPIN</td><td align="char" char="." valign="top">15,973</td><td align="char" char="." valign="top">16,102</td><td align="char" char="." valign="top">128</td><td align="char" char="." valign="top">16,052</td><td align="char" char="." valign="top">79</td><td align="char" char="." valign="top">50</td><td align="char" char="." valign="top">39</td></tr><tr><td align="left" valign="top">MISCAN</td><td align="char" char="." valign="top">15,748</td><td align="char" char="." valign="top">15,866</td><td align="char" char="." valign="top">117</td><td align="char" char="." valign="top">15,815</td><td align="char" char="." valign="top">66</td><td align="char" char="." valign="top">51</td><td align="char" char="." valign="top">43</td></tr><tr><td align="left" valign="top" rowspan="2">U70 | F3m</td><td align="left" valign="top">CRCSPIN</td><td align="char" char="." valign="top">15,973</td><td align="char" char="." valign="top">16,069</td><td align="char" char="." valign="top">95</td><td align="char" char="." valign="top">16,067</td><td align="char" char="." valign="top">93</td><td align="char" char="." valign="top">2</td><td align="char" char="." valign="top">2</td></tr><tr><td align="left" valign="top">MISCAN</td><td align="char" char="." valign="top">15,748</td><td align="char" char="." valign="top">15,840</td><td align="char" char="." valign="top">92</td><td align="char" char="." valign="top">15,833</td><td align="char" char="." valign="top">85</td><td align="char" char="." valign="top">7</td><td align="char" char="." valign="top">8</td></tr><tr><td align="left" valign="top" rowspan="2">U70 | F9m</td><td align="left" valign="top">CRCSPIN</td><td align="char" char="." valign="top">15,973</td><td align="char" char="." valign="top">16,069</td><td align="char" char="." valign="top">95</td><td align="char" char="." valign="top">16,063</td><td align="char" char="." valign="top">90</td><td align="char" char="." valign="top">5</td><td align="char" char="." valign="top">6</td></tr><tr><td align="left" valign="top">MISCAN</td><td align="char" char="." valign="top">15,748</td><td align="char" char="." valign="top">15,840</td><td align="char" char="." valign="top">92</td><td align="char" char="." valign="top">15,830</td><td align="char" char="." valign="top">81</td><td align="char" char="." valign="top">10</td><td align="char" char="." valign="top">11</td></tr><tr><td align="left" valign="top" rowspan="2">U70 | F18m</td><td align="left" valign="top">CRCSPIN</td><td align="char" char="." valign="top">15,973</td><td align="char" char="." valign="top">16,069</td><td align="char" char="." valign="top">95</td><td align="char" char="." valign="top">16,058</td><td align="char" char="." valign="top">84</td><td align="char" char="." valign="top">11</td><td align="char" char="." valign="top">12</td></tr><tr><td align="left" valign="top">MISCAN</td><td align="char" char="." valign="top">15,748</td><td align="char" char="." valign="top">15,840</td><td align="char" char="." valign="top">92</td><td align="char" char="." valign="top">15,824</td><td align="char" char="." valign="top">76</td><td align="char" char="." valign="top">16</td><td align="char" char="." valign="top">17</td></tr><tr><td align="left" valign="top" rowspan="2">C70 | C3m</td><td align="left" valign="top">CRCSPIN</td><td align="char" char="." valign="top">15,683</td><td align="char" char="." valign="top">15,968</td><td align="char" char="." valign="top">285</td><td align="char" char="." valign="top">15,968</td><td align="char" char="." valign="top">285</td><td align="char" char="." valign="top">0</td><td align="char" char="." valign="top">0</td></tr><tr><td align="left" valign="top">MISCAN</td><td align="char" char="." valign="top">15,590</td><td align="char" char="." valign="top">15,824</td><td align="char" char="." valign="top">234</td><td align="char" char="." valign="top">15,823</td><td align="char" char="." valign="top">234</td><td align="char" char="." valign="top">1</td><td align="char" char="." valign="top">0</td></tr><tr><td align="left" valign="top" rowspan="2">C70 | C9m</td><td align="left" valign="top">CRCSPIN</td><td align="char" char="." valign="top">15,683</td><td align="char" char="." valign="top">15,968</td><td align="char" char="." valign="top">285</td><td align="char" char="." valign="top">15,968</td><td align="char" char="." valign="top">285</td><td align="char" char="." valign="top">0</td><td align="char" char="." valign="top">0</td></tr><tr><td align="left" valign="top">MISCAN</td><td align="char" char="." valign="top">15,590</td><td align="char" char="." valign="top">15,824</td><td align="char" char="." valign="top">234</td><td align="char" char="." valign="top">15,823</td><td align="char" char="." valign="top">233</td><td align="char" char="." valign="top">1</td><td align="char" char="." valign="top">0</td></tr><tr><td align="left" valign="top" rowspan="2">C70 | C18m</td><td align="left" valign="top">CRCSPIN</td><td align="char" char="." valign="top">15,684</td><td align="char" char="." valign="top">15,969</td><td align="char" char="." valign="top">285</td><td align="char" char="." valign="top">15,968</td><td align="char" char="." valign="top">285</td><td align="char" char="." valign="top">0</td><td align="char" char="." valign="top">0</td></tr><tr><td align="left" valign="top">MISCAN</td><td align="char" char="." valign="top">15,589</td><td align="char" char="." valign="top">15,824</td><td align="char" char="." valign="top">234</td><td align="char" char="." valign="top">15,822</td><td align="char" char="." valign="top">233</td><td align="char" char="." valign="top">2</td><td align="char" char="." valign="top">1</td></tr><tr><td align="left" valign="top" rowspan="2">C70 | C@75</td><td align="left" valign="top">CRCSPIN</td><td align="char" char="." valign="top">15,683</td><td align="char" char="." valign="top">15,968</td><td align="char" char="." valign="top">285</td><td align="char" char="." valign="top">15,968</td><td align="char" char="." valign="top">285</td><td align="char" char="." valign="top">0</td><td align="char" char="." valign="top">0</td></tr><tr><td align="left" valign="top">MISCAN</td><td align="char" char="." valign="top">15,590</td><td align="char" char="." valign="top">15,824</td><td align="char" char="." valign="top">234</td><td align="char" char="." valign="top">15,819</td><td align="char" char="." valign="top">229</td><td align="char" char="." valign="top">5</td><td align="char" char="." valign="top">2</td></tr><tr><td align="left" valign="top" rowspan="2">C70 | F3m</td><td align="left" valign="top">CRCSPIN</td><td align="char" char="." valign="top">15,683</td><td align="char" char="." valign="top">15,968</td><td align="char" char="." valign="top">285</td><td align="char" char="." valign="top">15,964</td><td align="char" char="." valign="top">281</td><td align="char" char="." valign="top">5</td><td align="char" char="." valign="top">2</td></tr><tr><td align="left" valign="top">MISCAN</td><td align="char" char="." valign="top">15,590</td><td align="char" char="." valign="top">15,824</td><td align="char" char="." valign="top">234</td><td align="char" char="." valign="top">15,818</td><td align="char" char="." valign="top">228</td><td align="char" char="." valign="top">6</td><td align="char" char="." valign="top">3</td></tr><tr><td align="left" valign="top" rowspan="2">C70 | F9m</td><td align="left" valign="top">CRCSPIN</td><td align="char" char="." valign="top">15,683</td><td align="char" char="." valign="top">15,968</td><td align="char" char="." valign="top">285</td><td align="char" char="." valign="top">15,964</td><td align="char" char="." valign="top">281</td><td align="char" char="." valign="top">4</td><td align="char" char="." valign="top">1</td></tr><tr><td align="left" valign="top">MISCAN</td><td align="char" char="." valign="top">15,590</td><td align="char" char="." valign="top">15,824</td><td align="char" char="." valign="top">234</td><td align="char" char="." valign="top">15,817</td><td align="char" char="." valign="top">228</td><td align="char" char="." valign="top">7</td><td align="char" char="." valign="top">3</td></tr><tr><td align="left" valign="top" rowspan="2">C70 | F18m</td><td align="left" valign="top">CRCSPIN</td><td align="char" char="." valign="top">15,683</td><td align="char" char="." valign="top">15,968</td><td align="char" char="." valign="top">285</td><td align="char" char="." valign="top">15,964</td><td align="char" char="." valign="top">281</td><td align="char" char="." valign="top">4</td><td align="char" char="." valign="top">2</td></tr><tr><td align="left" valign="top">MISCAN</td><td align="char" char="." valign="top">15,589</td><td align="char" char="." valign="top">15,824</td><td align="char" char="." valign="top">234</td><td align="char" char="." valign="top">15,817</td><td align="char" char="." valign="top">227</td><td align="char" char="." valign="top">7</td><td align="char" char="." valign="top">3</td></tr><tr><td align="left" valign="top" rowspan="2">C70 | U</td><td align="left" valign="top">CRCSPIN</td><td align="char" char="." valign="top">15,683</td><td align="char" char="." valign="top">15,968</td><td align="char" char="." valign="top">285</td><td align="char" char="." valign="top">15,930</td><td align="char" char="." valign="top">247</td><td align="char" char="." valign="top">38</td><td align="char" char="." valign="top">13</td></tr><tr><td align="left" valign="top">MISCAN</td><td align="char" char="." valign="top">15,581</td><td align="char" char="." valign="top">15,815</td><td align="char" char="." valign="top">234</td><td align="char" char="." valign="top">15,726</td><td align="char" char="." valign="top">146</td><td align="char" char="." valign="top">89</td><td align="char" char="." valign="top">38</td></tr><tr><td align="left" valign="top" rowspan="2">F70 | F3m</td><td align="left" valign="top">CRCSPIN</td><td align="char" char="." valign="top">15,764</td><td align="char" char="." valign="top">16,024</td><td align="char" char="." valign="top">259</td><td align="char" char="." valign="top">16,023</td><td align="char" char="." valign="top">259</td><td align="char" char="." valign="top">0</td><td align="char" char="." valign="top">0</td></tr><tr><td align="left" valign="top">MISCAN</td><td align="char" char="." valign="top">15,676</td><td align="char" char="." valign="top">15,902</td><td align="char" char="." valign="top">226</td><td align="char" char="." valign="top">15,902</td><td align="char" char="." valign="top">226</td><td align="char" char="." valign="top">0</td><td align="char" char="." valign="top">0</td></tr><tr><td align="left" valign="top" rowspan="2">F70 | F9m</td><td align="left" valign="top">CRCSPIN</td><td align="char" char="." valign="top">15,765</td><td align="char" char="." valign="top">16,024</td><td align="char" char="." valign="top">259</td><td align="char" char="." valign="top">16,023</td><td align="char" char="." valign="top">259</td><td align="char" char="." valign="top">1</td><td align="char" char="." valign="top">0</td></tr><tr><td align="left" valign="top">MISCAN</td><td align="char" char="." valign="top">15,677</td><td align="char" char="." valign="top">15,903</td><td align="char" char="." valign="top">226</td><td align="char" char="." valign="top">15,903</td><td align="char" char="." valign="top">225</td><td align="char" char="." valign="top">1</td><td align="char" char="." valign="top">0</td></tr><tr><td align="left" valign="top" rowspan="2">F70 | F18m</td><td align="left" valign="top">CRCSPIN</td><td align="char" char="." valign="top">15,766</td><td align="char" char="." valign="top">16,025</td><td align="char" char="." valign="top">259</td><td align="char" char="." valign="top">16,024</td><td align="char" char="." valign="top">258</td><td align="char" char="." valign="top">1</td><td align="char" char="." valign="top">0</td></tr><tr><td align="left" valign="top">MISCAN</td><td align="char" char="." valign="top">15,677</td><td align="char" char="." valign="top">15,903</td><td align="char" char="." valign="top">226</td><td align="char" char="." valign="top">15,903</td><td align="char" char="." valign="top">226</td><td align="char" char="." valign="top">0</td><td align="char" char="." valign="top">0</td></tr><tr><td align="left" valign="top" rowspan="2">F70 | U</td><td align="left" valign="top">CRCSPIN</td><td align="char" char="." valign="top">15,764</td><td align="char" char="." valign="top">16,024</td><td align="char" char="." valign="top">259</td><td align="char" char="." valign="top">15,990</td><td align="char" char="." valign="top">226</td><td align="char" char="." valign="top">33</td><td align="char" char="." valign="top">13</td></tr><tr><td align="left" valign="top">MISCAN</td><td align="char" char="." valign="top">15,677</td><td align="char" char="." valign="top">15,903</td><td align="char" char="." valign="top">226</td><td align="char" char="." valign="top">15,873</td><td align="char" char="." valign="top">196</td><td align="char" char="." valign="top">30</td><td align="char" char="." valign="top">13</td></tr></tbody></table><table-wrap-foot><fn><p>Notes: Outcomes calculated over the lifetime of a cohort of 1000 average-risk, CRC-free individuals with age at pandemic defined in the scenario description. The scenario column describes colorectal cancer screening disruption scenarios, as presented in <xref ref-type="table" rid="table1">Table 1</xref>. Life-years (LY) and Life-years gained (LYG) are computed over the remaining lifespan of individuals starting at the beginning of 2020. All values refer to cohort-level estimates – that is, the expected LY of an average-risk person. This table presents results assuming high colonoscopy sensitivity. <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref> presents additional results for the low colonoscopy sensitivity scenario, and <xref ref-type="supplementary-material" rid="supp2 supp3">Supplementary files 2 and 3</xref> present CRC cases and deaths outcomes.</p></fn></table-wrap-foot></table-wrap><p>Similarly, 60-year-olds are expected to incur a substantial reduction in the benefit of screening if screening is discontinued after the pandemic. Those who started screening at age 50 and stopped after the pandemic are expected to lose 106–124 or 92–111 LY per 1000 individuals if pursuing a colonoscopy (C60 | U) or a FIT (F60 | U) screening regimen, respectively. Those who were semi-adherent to FIT screening before the pandemic and discontinued screening (f60 | U) lose even more LY – from 143 to 149 LY per 1000 individuals, or 58–69% of the benefit of screening. Similarly, unscreened 60-year-olds who start screening at age 65 (scenario U60 | C@65) are predicted to lose 42–45 LY per 1000 individuals compared to a scenario where they would have begun screening at age 60 – a 20–22% loss in LYG from screening due to this disruption.</p><p>Switching the screening regimen from colonoscopy to FIT and short-term delays will cause only a modest reduction in the benefit of screening. For the 60-year-old cohort, switching from colonoscopy to annual FIT after the pandemic with an 18-month delay is expected to result in a loss of 9–11 LY per 1000 individuals, a 3–4% loss relative to a scenario with no change in screening regimen and no delays. Similarly, short-term delays are predicted to cause minimal decreases in the benefits of the screening program. A 3-month delay in colonoscopy screening results in a loss of 0–2 LY per 1000 individuals for the 60-year cohort (scenarios C60 | C3m), whereas a 9- or 18-month delay (C60 | C9m and C60 | C18m) is expected to result in a loss of 0–2 or 0–3 LY per 1000 individuals, respectively. The worst-case scenario of an 18-month pause starting in March 2020 (scenario C60 | C18m) resulted in a 0–1% loss of the benefit of screening.</p><p>Seventy-year-olds lose fewer LY due to screening disruptions but can still be affected by the pandemic as they are at greater risk for CRC than younger age groups. When discontinuing screening after the pandemic, 70-year-olds are expected to lose 38–87 or 29–33 LY per 1000 individuals due to the pandemic if pursuing a colonoscopy (C70 | U) or FIT (F70 | U) screening regimen, respectively. Unscreened 70-year-olds who only come back to screening at age 75 (scenario U70 | C@75) are expected to lose 49–50 LY per 1000 individuals, a 39–43% reduction in LYG relative to a scenario where they would have received colonoscopy screening at age 70.</p><p>Seventy-year-olds who were up-to-date with their screening and experienced short-term delays of up to 18 months can expect minimal loss of LY due to pandemic-induced CRC screening disruptions, even if they switch to FIT after the pandemic. Those who transitioned from colonoscopy to FIT screening at age 70 can expect a reduction of 5–7 LY per 1000 individuals even if a return to FIT screening was delayed by 18 months (scenario C70 | F18m). This reduction in benefit represents a 2–3% reduction in LYG of colonoscopy-only screening.</p><sec id="s3-1"><title>Low-sensitivity scenarios</title><p>While colonoscopy sensitivity affects the overall benefit of screening, <italic>conditional on colonoscopy sensitivity</italic>, the loss of LY due to pandemic-induced scenarios is similar across sensitivity levels. <xref ref-type="fig" rid="fig2">Figure 2</xref> compares LYG and LYL for high- and low-sensitivity scenarios. High-sensitivity scenarios are expected to yield higher LYG benefits than low-sensitivity scenarios, and the magnitude of this difference is higher for more intensive screening regimens. For 60-year-olds with a prior colonoscopy at age 50 who experience an 18-month delay during the pandemic (scenario C60 | C 18m), the benefit of screening is 240–297 LYG per 1000 individuals under a <italic>high colonoscopy sensitivity</italic> scenario, whereas it is 217–272 under a <italic>low colonoscopy sensitivity</italic> scenario.</p><fig-group><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>Life-years gained (LYG) in high- vs. low-sensitivity scenarios.</title><p>Notes<italic>:</italic> Each dot represents one scenario considered in this study. The horizontal axis displays the number of LYG estimated in that scenario under a high colonoscopy sensitivity scenario. The vertical axis shows the results for the same cohort under a low colonoscopy sensitivity scenario. If sensitivity did not affect the estimate, then all points would be on top of a 45-degree line. Different colors represent CRCSPIN and MISCAN models.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-85264-fig2-v1.tif"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 1.</label><caption><title>Life-years lost in high- vs. low-sensitivity scenarios.</title><p>Notes: Each dot represents one scenario considered in this study. The horizontal axis displays the number of life-years lost due to disruptions (LYL) estimated in that scenario under a high colonoscopy sensitivity scenario. The vertical axis shows the results for the same cohort under a low colonoscopy sensitivity scenario. If sensitivity did not affect the estimate, then all points would be on top of a 45-degree line. Different colors represent CRCSPIN and MISCAN models.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-85264-fig2-figsupp1-v1.tif"/></fig></fig-group><p>Nevertheless, conditional on the sensitivity scenario, the effect of pandemic disruptions on LY lost is expected to be very similar for low-sensitivity scenarios. An 18-month delay in colonoscopy screening is expected to result in a loss of 0–3 LY per 1000 individuals for 60-year-olds assuming high sensitivity, whereas it is expected to result in a loss of 0–4 LY per 1000 individuals assuming low sensitivity.</p></sec></sec><sec id="s4" sec-type="discussion"><title>Discussion</title><p>Model-based screening cost-effectiveness analyses present estimates under guideline-concordant scenarios, but there are many reasons why real-world screening will not follow guidelines. Chief among them in 2020, the COVID-19 pandemic severely disrupted screening. Under those conditions, disparities in health outcomes can arise if disruptions are unevenly distributed in the population.</p><p>Our results suggest that the COVID-19 pandemic will have an uneven effect on CRC outcomes depending on whether and how fast screening is resumed after the pandemic onset. Consider three cohorts with the same pre-pandemic screening regimen and behavior: 60-year-olds with a prior colonoscopy at age 50. Cohorts that experience short-term disruptions (e.g. 3–18 months) only experience a small loss of life due to short-term delays – up to 3 LY per 1000 individuals. Those who switch from colonoscopy to FIT screening are projected to experience a greater loss of life – from 9 to 11 to LY per 1000 individuals. If screening is only resumed at age 65 (e.g. age at Medicare enrollment) or abandoned, the loss of benefits from screening could be 3–11 LY per 1000 individuals (scenario C60 | C@65). Lastly, discontinuing screening after the pandemic is projected to cause a loss of 106–124 LY per 1000 individuals, a decrease of 36–51% in the benefit of screening (scenario C60 | U). These results imply that the pandemic will become a disparity-widening mechanism if it differentially affects screening access and/or behavior across different population groups. These results also show that the pandemic is unlikely to substantially affect those whose screening is only interrupted momentarily.</p><p>These results highlight the potential implications of disruptions to preventative care due to loss of insurance following the pandemic. According to data from the Bureau of Labor Statistics Current Population Survey, more dramatic declines in the number employed during the COVID-19 pandemic were seen in Black, Asian American, and Hispanic groups (<xref ref-type="bibr" rid="bib7">Gemelas et al., 2022</xref>). Moreover, data from the US Census Household Pulse Survey suggests that Black and Hispanic workers were not only more likely to be unemployed but were also more likely to be without unemployment insurance (<xref ref-type="bibr" rid="bib17">Mar et al., 2022</xref>). These results provide important clinical insight on the projected impact of these populations which may guide future policy on the aftereffects of the pandemic. Those who were previously uninsured for long periods of time throughout the pandemic should resume CRC screening to mitigate the long-term effects projected in these simulations.</p><p>These results also add to the growing evidence of the implications of delayed CRC care following the COVID-19 pandemic. A microsimulation study based on a Canadian population explored scenarios of differing screening delays and transition periods due to attenuated screening volumes and found that a 6-month delay in primary screening could increase CRC incidence by 2200 cases and 960 more cancer deaths over a lifetime (<xref ref-type="bibr" rid="bib28">Yong et al., 2021</xref>). A microsimulation paper based on a Chilean population illustrated similar results with respect to CRC incidence and mortality due to the screening backlog and strained patient care during the pandemic (<xref ref-type="bibr" rid="bib26">Ward et al., 2021</xref>). Our results mirror these conclusions and provide new scenarios which consider the aftereffects of loss of healthcare insurance due to disparities magnified by the COVID-19 pandemic.</p><sec id="s4-1"><title>Limitations</title><p>This analysis presents a series of limitations. First, we do not present population-level estimates of reductions in benefits. While doing so could prove helpful, one would have to estimate how many people will be screened following each scenario we modeled. That would require individual-level data describing the distribution of delays and screening regimen switching in the population after the pandemic, which will not be available for many years. Instead of pursuing a population-level study, we conditioned our estimates on a discrete set of pre-specified disruption scenarios. This approach makes our study feasible but prevents us from making population-level predictions. Moreover, our approach does not account for potential correlation between risk factors and disruptions – we only provide estimates using models calibrated to represent cohorts with average risk.</p><p>Second, the scenarios presented in this analysis represent only a subset of the real-world changes in screening due to the pandemic. Even in the absence of a pandemic, individuals may switch from colonoscopy to FIT, and return to colonoscopy screening. To keep this analysis tractable, we restrict the variations considered in this paper to one switch from colonoscopy to FIT. Further, we only consider changes in screening regimens immediately following the COVID-19 pandemic. Third, this analysis only considers uncertainty stemming from structural differences between models and two scenarios of test characteristics and does not evaluate parameter or sampling uncertainty. Our estimates represent the expected value of estimates conditional on scenarios across an average-risk cohort drawn from the general US population.</p><p>Finally, this paper identifies the effect of disruptions on the effectiveness of screening interventions but does not explicitly identify policy interventions or prioritization rules to amend those inequities. Future research could use extended cost-effectiveness analysis to evaluate CRC screening interventions in the context of healthcare disparities (<xref ref-type="bibr" rid="bib1">Asaria et al., 2016</xref>; <xref ref-type="bibr" rid="bib20">Richard et al., 2020</xref>).</p></sec><sec id="s4-2"><title>Conclusion</title><p>This study quantified the potential effect of disruptions to colonoscopy screening and demonstrated that unequal recovery of CRC screening following the pandemic will predictably widen disparities in CRC outcomes. The COVID-19 pandemic will severely reduce the benefits of CRC screening if it causes screening discontinuation or long-term (e.g. 5 year) delays. Short-term delays of 3–18 months and regime switching from colonoscopy to FIT are not expected to have significant consequences.</p></sec></sec></body><back><sec sec-type="additional-information" id="s5"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn><fn fn-type="COI-statement" id="conf2"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Data curation, Software, Formal analysis, Investigation, Visualization, Methodology, Writing – original draft, Project administration, Writing – review and editing</p></fn><fn fn-type="con" id="con2"><p>Conceptualization, Software, Formal analysis, Investigation, Methodology, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con3"><p>Conceptualization, Investigation, Methodology, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con4"><p>Software, Writing – review and editing</p></fn><fn fn-type="con" id="con5"><p>Resources, Software, Writing – review and editing</p></fn><fn fn-type="con" id="con6"><p>Resources, Software, Writing – review and editing</p></fn><fn fn-type="con" id="con7"><p>Funding acquisition, Methodology, Writing – review and editing</p></fn><fn fn-type="con" id="con8"><p>Conceptualization, Funding acquisition, Methodology, Writing – review and editing</p></fn><fn fn-type="con" id="con9"><p>Conceptualization, Funding acquisition, Investigation, Methodology, Writing – review and editing</p></fn></fn-group></sec><sec sec-type="supplementary-material" id="s6"><title>Additional files</title><supplementary-material id="mdar"><label>MDAR checklist</label><media xlink:href="elife-85264-mdarchecklist1-v1.pdf" mimetype="application" mime-subtype="pdf"/></supplementary-material><supplementary-material id="supp1"><label>Supplementary file 1.</label><caption><title>Projected lifetime life-years (LY) per 1,000 individuals.</title></caption><media xlink:href="elife-85264-supp1-v1.xlsx" mimetype="application" mime-subtype="xlsx"/></supplementary-material><supplementary-material id="supp2"><label>Supplementary file 2.</label><caption><title>Projected lifetime CRC cases per 1,000 individuals.</title></caption><media xlink:href="elife-85264-supp2-v1.xlsx" mimetype="application" mime-subtype="xlsx"/></supplementary-material><supplementary-material id="supp3"><label>Supplementary file 3.</label><caption><title>Projected lifetime CRC deaths per 1,000 individuals.</title></caption><media xlink:href="elife-85264-supp3-v1.xlsx" mimetype="application" mime-subtype="xlsx"/></supplementary-material></sec><sec sec-type="data-availability" id="s7"><title>Data availability</title><p>This is a computational study based on two independently developed simulation models. Simulation output data and code used to produce the figures and Supplementary Table 3 in this paper are available at <ext-link ext-link-type="uri" xlink:href="https://github.com/c-rutter/unequal-recovery-covid-19">https://github.com/c-rutter/unequal-recovery-covid-19</ext-link>, (copy archived at <ext-link ext-link-type="uri" xlink:href="https://archive.softwareheritage.org/swh:1:dir:306da61dce0c8698a05fe4db1d69e5a90d38af21;origin=https://github.com/c-rutter/unequal-recovery-covid-19;visit=swh:1:snp:33a42ff2b45f719249a647178eca5416ccb34a67;anchor=swh:1:rev:0244d3219552031e056f7b5d6aa02fe03276080d">swh:1:rev:0244d3219552031e056f7b5d6aa02fe03276080d</ext-link>). Full documentation of CISNET models used to produce the results presented in this study can be found at <ext-link ext-link-type="uri" xlink:href="https://cisnet.cancer.gov/colorectal/profiles.html">https://cisnet.cancer.gov/colorectal/profiles.html</ext-link>. Interested researchers can contact authors directly for more insight into the CISNET models.</p></sec><ack id="ack"><title>Acknowledgements</title><p>This research was supported by grant U01-CA253913 from the National Cancer Institute (NCI) as part of the Cancer Intervention and Surveillance Modeling Network (CISNET). Dr. Zauber and Ms. Hahn were supported in part by NCI CCSG P30CA008748 (PI: Vickers). This research used resources of the Argonne Leadership Computing Facility, which is a DOE Office of Science User Facility supported under Contract DE-AC02-06CH11357. We would like to thank the Argonne Leadership Computing Facility staff for their timely and critical support. This research was completed with resources provided by the Laboratory Computing Resource Center at Argonne National Laboratory. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Asaria</surname><given-names>M</given-names></name><name><surname>Griffin</surname><given-names>S</given-names></name><name><surname>Cookson</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Distributional cost-effectiveness analysis: a tutorial</article-title><source>Medical Decision Making</source><volume>36</volume><fpage>8</fpage><lpage>19</lpage><pub-id pub-id-type="doi">10.1177/0272989X15583266</pub-id><pub-id pub-id-type="pmid">25908564</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Choy</surname><given-names>AM</given-names></name><name><surname>Lebwohl</surname><given-names>B</given-names></name><name><surname>Krigel</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Impact of social determinants of health on colorectal cancer screening and surveillance in the covid reopening phase</article-title><source>European Journal of Gastroenterology &amp; Hepatology</source><volume>34</volume><fpage>739</fpage><lpage>743</lpage><pub-id pub-id-type="doi">10.1097/MEG.0000000000002350</pub-id><pub-id pub-id-type="pmid">35102113</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davidson</surname><given-names>KW</given-names></name><name><surname>Barry</surname><given-names>MJ</given-names></name><name><surname>Mangione</surname><given-names>CM</given-names></name><name><surname>Cabana</surname><given-names>M</given-names></name><name><surname>Caughey</surname><given-names>AB</given-names></name><name><surname>Davis</surname><given-names>EM</given-names></name><name><surname>Donahue</surname><given-names>KE</given-names></name><name><surname>Doubeni</surname><given-names>CA</given-names></name><name><surname>Krist</surname><given-names>AH</given-names></name><name><surname>Kubik</surname><given-names>M</given-names></name><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Ogedegbe</surname><given-names>G</given-names></name><name><surname>Owens</surname><given-names>DK</given-names></name><name><surname>Pbert</surname><given-names>L</given-names></name><name><surname>Silverstein</surname><given-names>M</given-names></name><name><surname>Stevermer</surname><given-names>J</given-names></name><name><surname>Tseng</surname><given-names>C-W</given-names></name><name><surname>Wong</surname><given-names>JB</given-names></name><collab>US Preventive Services Task Force</collab></person-group><year iso-8601-date="2021">2021</year><article-title>Screening for colorectal cancer: US preventive services Task force recommendation statement</article-title><source>JAMA</source><volume>325</volume><fpage>1965</fpage><lpage>1977</lpage><pub-id pub-id-type="doi">10.1001/jama.2021.6238</pub-id><pub-id pub-id-type="pmid">34003218</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Del Vecchio Blanco</surname><given-names>G</given-names></name><name><surname>Calabrese</surname><given-names>E</given-names></name><name><surname>Biancone</surname><given-names>L</given-names></name><name><surname>Monteleone</surname><given-names>G</given-names></name><name><surname>Paoluzi</surname><given-names>OA</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>The impact of COVID-19 pandemic in the colorectal cancer prevention</article-title><source>International Journal of Colorectal Disease</source><volume>35</volume><fpage>1951</fpage><lpage>1954</lpage><pub-id pub-id-type="doi">10.1007/s00384-020-03635-6</pub-id><pub-id pub-id-type="pmid">32500432</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Edwards</surname><given-names>BK</given-names></name><name><surname>Ward</surname><given-names>E</given-names></name><name><surname>Kohler</surname><given-names>BA</given-names></name><name><surname>Eheman</surname><given-names>C</given-names></name><name><surname>Zauber</surname><given-names>AG</given-names></name><name><surname>Anderson</surname><given-names>RN</given-names></name><name><surname>Jemal</surname><given-names>A</given-names></name><name><surname>Schymura</surname><given-names>MJ</given-names></name><name><surname>Lansdorp-Vogelaar</surname><given-names>I</given-names></name><name><surname>Seeff</surname><given-names>LC</given-names></name><name><surname>van Ballegooijen</surname><given-names>M</given-names></name><name><surname>Goede</surname><given-names>SL</given-names></name><name><surname>Ries</surname><given-names>LAG</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Annual report to the nation on the status of cancer, 1975-2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates</article-title><source>Cancer</source><volume>116</volume><fpage>544</fpage><lpage>573</lpage><pub-id pub-id-type="doi">10.1002/cncr.24760</pub-id><pub-id pub-id-type="pmid">19998273</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fedewa</surname><given-names>SA</given-names></name><name><surname>Yabroff</surname><given-names>KR</given-names></name><name><surname>Bandi</surname><given-names>P</given-names></name><name><surname>Smith</surname><given-names>RA</given-names></name><name><surname>Nargis</surname><given-names>N</given-names></name><name><surname>Zheng</surname><given-names>Z</given-names></name><name><surname>Drope</surname><given-names>J</given-names></name><name><surname>Jemal</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Unemployment and cancer screening: baseline estimates to inform health care delivery in the context of covid-19 economic distress</article-title><source>Cancer</source><volume>128</volume><fpage>737</fpage><lpage>745</lpage><pub-id pub-id-type="doi">10.1002/cncr.33966</pub-id><pub-id pub-id-type="pmid">34747008</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gemelas</surname><given-names>J</given-names></name><name><surname>Davison</surname><given-names>J</given-names></name><name><surname>Keltner</surname><given-names>C</given-names></name><name><surname>Ing</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Inequities in employment by race, ethnicity, and sector during COVID-19</article-title><source>Journal of Racial and Ethnic Health Disparities</source><volume>9</volume><fpage>350</fpage><lpage>355</lpage><pub-id pub-id-type="doi">10.1007/s40615-021-00963-3</pub-id><pub-id pub-id-type="pmid">33452573</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gupta</surname><given-names>S</given-names></name><name><surname>Lieberman</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Screening and surveillance colonoscopy and COVID-19: avoiding more casualties</article-title><source>Gastroenterology</source><volume>159</volume><fpage>1205</fpage><lpage>1208</lpage><pub-id pub-id-type="doi">10.1053/j.gastro.2020.06.091</pub-id><pub-id pub-id-type="pmid">32682766</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gupta</surname><given-names>S</given-names></name><name><surname>Shahidi</surname><given-names>N</given-names></name><name><surname>Gilroy</surname><given-names>N</given-names></name><name><surname>Rex</surname><given-names>DK</given-names></name><name><surname>Burgess</surname><given-names>NG</given-names></name><name><surname>Bourke</surname><given-names>MJ</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Proposal for the return to routine endoscopy during the COVID-19 pandemic</article-title><source>Gastrointestinal Endoscopy</source><volume>92</volume><fpage>735</fpage><lpage>742</lpage><pub-id pub-id-type="doi">10.1016/j.gie.2020.04.050</pub-id><pub-id pub-id-type="pmid">32360301</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="web"><person-group person-group-type="author"><collab>Johns Hopkins Univerity &amp; Medicine Coronavirus Resource Center</collab></person-group><year iso-8601-date="2022">2022</year><article-title>COVID-19 Dashboard</article-title><ext-link ext-link-type="uri" xlink:href="https://coronavirus.jhu.edu/map.html">https://coronavirus.jhu.edu/map.html</ext-link><date-in-citation iso-8601-date="2022-11-10">November 10, 2022</date-in-citation></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Knudsen</surname><given-names>AB</given-names></name><name><surname>Zauber</surname><given-names>AG</given-names></name><name><surname>Rutter</surname><given-names>CM</given-names></name><name><surname>Naber</surname><given-names>SK</given-names></name><name><surname>Doria-Rose</surname><given-names>VP</given-names></name><name><surname>Pabiniak</surname><given-names>C</given-names></name><name><surname>Johanson</surname><given-names>C</given-names></name><name><surname>Fischer</surname><given-names>SE</given-names></name><name><surname>Lansdorp-Vogelaar</surname><given-names>I</given-names></name><name><surname>Kuntz</surname><given-names>KM</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Estimation of benefits, burden, and harms of colorectal cancer screening strategies: modeling study for the US preventive services Task force</article-title><source>JAMA</source><volume>315</volume><fpage>2595</fpage><lpage>2609</lpage><pub-id pub-id-type="doi">10.1001/jama.2016.6828</pub-id><pub-id pub-id-type="pmid">27305518</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Knudsen</surname><given-names>AB</given-names></name><name><surname>Rutter</surname><given-names>CM</given-names></name><name><surname>Peterse</surname><given-names>EFP</given-names></name><name><surname>Lietz</surname><given-names>AP</given-names></name><name><surname>Seguin</surname><given-names>CL</given-names></name><name><surname>Meester</surname><given-names>RGS</given-names></name><name><surname>Perdue</surname><given-names>LA</given-names></name><name><surname>Lin</surname><given-names>JS</given-names></name><name><surname>Siegel</surname><given-names>RL</given-names></name><name><surname>Doria-Rose</surname><given-names>VP</given-names></name><name><surname>Feuer</surname><given-names>EJ</given-names></name><name><surname>Zauber</surname><given-names>AG</given-names></name><name><surname>Kuntz</surname><given-names>KM</given-names></name><name><surname>Lansdorp-Vogelaar</surname><given-names>I</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Colorectal cancer screening: an updated modeling study for the US preventive services Task force</article-title><source>JAMA</source><volume>325</volume><fpage>1998</fpage><lpage>2011</lpage><pub-id pub-id-type="doi">10.1001/jama.2021.5746</pub-id><pub-id pub-id-type="pmid">34003219</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lansdorp-Vogelaar</surname><given-names>I</given-names></name><name><surname>Knudsen</surname><given-names>AB</given-names></name><name><surname>Brenner</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Cost-Effectiveness of colorectal cancer screening</article-title><source>Epidemiologic Reviews</source><volume>33</volume><fpage>88</fpage><lpage>100</lpage><pub-id pub-id-type="doi">10.1093/epirev/mxr004</pub-id><pub-id pub-id-type="pmid">21633092</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>JS</given-names></name><name><surname>Perdue</surname><given-names>LA</given-names></name><name><surname>Henrikson</surname><given-names>NB</given-names></name><name><surname>Bean</surname><given-names>SI</given-names></name><name><surname>Blasi</surname><given-names>PR</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Screening for colorectal cancer: updated evidence report and systematic review for the US preventive services Task force</article-title><source>JAMA</source><volume>325</volume><fpage>1978</fpage><lpage>1998</lpage><pub-id pub-id-type="doi">10.1001/jama.2021.4417</pub-id><pub-id pub-id-type="pmid">34003220</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Loeve</surname><given-names>F</given-names></name><name><surname>Boer</surname><given-names>R</given-names></name><name><surname>van Oortmarssen</surname><given-names>GJ</given-names></name><name><surname>van Ballegooijen</surname><given-names>M</given-names></name><name><surname>Habbema</surname><given-names>JD</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>The miscan-colon simulation model for the evaluation of colorectal cancer screening</article-title><source>Computers and Biomedical Research, an International Journal</source><volume>32</volume><fpage>13</fpage><lpage>33</lpage><pub-id pub-id-type="doi">10.1006/cbmr.1998.1498</pub-id><pub-id pub-id-type="pmid">10066353</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>London</surname><given-names>JW</given-names></name><name><surname>Fazio-Eynullayeva</surname><given-names>E</given-names></name><name><surname>Palchuk</surname><given-names>MB</given-names></name><name><surname>McNair</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Evolving effect of the COVID-19 pandemic on cancer-related encounters</article-title><source>JCO Clinical Cancer Informatics</source><volume>6</volume><elocation-id>e2100200</elocation-id><pub-id pub-id-type="doi">10.1200/CCI.21.00200</pub-id><pub-id pub-id-type="pmid">35258986</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mar</surname><given-names>D</given-names></name><name><surname>Ong</surname><given-names>P</given-names></name><name><surname>Larson</surname><given-names>T</given-names></name><name><surname>Peoples</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Racial and ethnic disparities in who receives unemployment benefits during COVID-19</article-title><source>SN Business &amp; Economics</source><volume>2</volume><elocation-id>102</elocation-id><pub-id pub-id-type="doi">10.1007/s43546-022-00283-6</pub-id><pub-id pub-id-type="pmid">35910458</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marcondes</surname><given-names>FO</given-names></name><name><surname>Cheng</surname><given-names>D</given-names></name><name><surname>Warner</surname><given-names>ET</given-names></name><name><surname>Kamran</surname><given-names>SC</given-names></name><name><surname>Haas</surname><given-names>JS</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>The trajectory of racial/ethnic disparities in the use of cancer screening before and during the COVID-19 pandemic: a large U.S. academic center analysis</article-title><source>Preventive Medicine</source><volume>151</volume><elocation-id>106640</elocation-id><pub-id pub-id-type="doi">10.1016/j.ypmed.2021.106640</pub-id><pub-id pub-id-type="pmid">34217419</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ong</surname><given-names>MBH</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Epic EHR data: cancer screenings nosedive in 2021 despite easing of COVID restrictions</article-title><source>The Cancer Letter</source><volume>1</volume><fpage>3</fpage><lpage>7</lpage></element-citation></ref><ref id="bib20"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Richard</surname><given-names>C</given-names></name><name><surname>Susan</surname><given-names>G</given-names></name><name><surname>Ole</surname><given-names>N</given-names></name><name><surname>Anthony</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2020">2020</year><source>Distributional Cost-Effectiveness Analysis: Quantifying Health Equity Impacts and Trade-Offs</source><publisher-name>Oxford University Press</publisher-name></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rutter</surname><given-names>CM</given-names></name><name><surname>Ozik</surname><given-names>J</given-names></name><name><surname>DeYoreo</surname><given-names>M</given-names></name><name><surname>Collier</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>MICROSIMULATION model calibration using incremental mixture approximate Bayesian computation</article-title><source>The Annals of Applied Statistics</source><volume>13</volume><fpage>2189</fpage><lpage>2212</lpage><pub-id pub-id-type="doi">10.1214/19-aoas1279</pub-id><pub-id pub-id-type="pmid">34691351</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rutter</surname><given-names>CM</given-names></name><name><surname>Nascimento de Lima</surname><given-names>P</given-names></name><name><surname>Lee</surname><given-names>JK</given-names></name><name><surname>Ozik</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Too good to be true? evaluation of colonoscopy sensitivity assumptions used in policy models</article-title><source>Cancer Epidemiology, Biomarkers &amp; Prevention</source><volume>31</volume><fpage>775</fpage><lpage>782</lpage><pub-id pub-id-type="doi">10.1158/1055-9965.EPI-21-1001</pub-id><pub-id pub-id-type="pmid">34906968</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shapiro</surname><given-names>JA</given-names></name><name><surname>Soman</surname><given-names>AV</given-names></name><name><surname>Berkowitz</surname><given-names>Z</given-names></name><name><surname>Fedewa</surname><given-names>SA</given-names></name><name><surname>Sabatino</surname><given-names>SA</given-names></name><name><surname>de Moor</surname><given-names>JS</given-names></name><name><surname>Clarke</surname><given-names>TC</given-names></name><name><surname>Doria-Rose</surname><given-names>VP</given-names></name><name><surname>Breslau</surname><given-names>ES</given-names></name><name><surname>Jemal</surname><given-names>A</given-names></name><name><surname>Nadel</surname><given-names>MR</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Screening for colorectal cancer in the United States: correlates and time trends by type of test</article-title><source>Cancer Epidemiology, Biomarkers &amp; Prevention</source><volume>30</volume><fpage>1554</fpage><lpage>1565</lpage><pub-id pub-id-type="doi">10.1158/1055-9965.EPI-20-1809</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Siegel</surname><given-names>RL</given-names></name><name><surname>Wagle</surname><given-names>NS</given-names></name><name><surname>Cercek</surname><given-names>A</given-names></name><name><surname>Smith</surname><given-names>RA</given-names></name><name><surname>Jemal</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Colorectal cancer statistics, 2023</article-title><source>CA: A Cancer Journal for Clinicians</source><volume>1</volume><elocation-id>21772</elocation-id><pub-id pub-id-type="doi">10.3322/caac.21772</pub-id><pub-id pub-id-type="pmid">36856579</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Hees</surname><given-names>F</given-names></name><name><surname>Habbema</surname><given-names>JDF</given-names></name><name><surname>Meester</surname><given-names>RG</given-names></name><name><surname>Lansdorp-Vogelaar</surname><given-names>I</given-names></name><name><surname>van Ballegooijen</surname><given-names>M</given-names></name><name><surname>Zauber</surname><given-names>AG</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Should colorectal cancer screening be considered in elderly persons without previous screening? A cost-effectiveness analysis</article-title><source>Annals of Internal Medicine</source><volume>160</volume><fpage>750</fpage><lpage>759</lpage><pub-id pub-id-type="doi">10.7326/M13-2263</pub-id><pub-id pub-id-type="pmid">24887616</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ward</surname><given-names>ZJ</given-names></name><name><surname>Walbaum</surname><given-names>M</given-names></name><name><surname>Walbaum</surname><given-names>B</given-names></name><name><surname>Guzman</surname><given-names>MJ</given-names></name><name><surname>Jimenez de la Jara</surname><given-names>J</given-names></name><name><surname>Nervi</surname><given-names>B</given-names></name><name><surname>Atun</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Estimating the impact of the COVID-19 pandemic on diagnosis and survival of five cancers in Chile from 2020 to 2030: a simulation-based analysis</article-title><source>The Lancet. Oncology</source><volume>22</volume><fpage>1427</fpage><lpage>1437</lpage><pub-id pub-id-type="doi">10.1016/S1470-2045(21)00426-5</pub-id><pub-id pub-id-type="pmid">34487693</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wilensky</surname><given-names>GR</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>The COVID-19 pandemic and the US health care workforce</article-title><source>JAMA Health Forum</source><volume>3</volume><elocation-id>e220001</elocation-id><pub-id pub-id-type="doi">10.1001/jamahealthforum.2022.0001</pub-id><pub-id pub-id-type="pmid">36218860</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yong</surname><given-names>JH</given-names></name><name><surname>Mainprize</surname><given-names>JG</given-names></name><name><surname>Yaffe</surname><given-names>MJ</given-names></name><name><surname>Ruan</surname><given-names>Y</given-names></name><name><surname>Poirier</surname><given-names>AE</given-names></name><name><surname>Coldman</surname><given-names>A</given-names></name><name><surname>Nadeau</surname><given-names>C</given-names></name><name><surname>Iragorri</surname><given-names>N</given-names></name><name><surname>Hilsden</surname><given-names>RJ</given-names></name><name><surname>Brenner</surname><given-names>DR</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>The impact of episodic screening interruption: COVID-19 and population-based cancer screening in Canada</article-title><source>Journal of Medical Screening</source><volume>28</volume><fpage>100</fpage><lpage>107</lpage><pub-id pub-id-type="doi">10.1177/0969141320974711</pub-id><pub-id pub-id-type="pmid">33241760</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zauber</surname><given-names>AG</given-names></name><name><surname>Lansdorp-Vogelaar</surname><given-names>I</given-names></name><name><surname>Knudsen</surname><given-names>AB</given-names></name><name><surname>Wilschut</surname><given-names>J</given-names></name><name><surname>van Ballegooijen</surname><given-names>M</given-names></name><name><surname>Kuntz</surname><given-names>KM</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Evaluating test strategies for colorectal cancer screening: a decision analysis for the U.S. preventive services Task force</article-title><source>Annals of Internal Medicine</source><volume>149</volume><fpage>659</fpage><lpage>669</lpage><pub-id pub-id-type="doi">10.7326/0003-4819-149-9-200811040-00244</pub-id><pub-id pub-id-type="pmid">18838717</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zauber</surname><given-names>AG</given-names></name><name><surname>Winawer</surname><given-names>SJ</given-names></name><name><surname>O’Brien</surname><given-names>MJ</given-names></name><name><surname>Lansdorp-Vogelaar</surname><given-names>I</given-names></name><name><surname>van Ballegooijen</surname><given-names>M</given-names></name><name><surname>Hankey</surname><given-names>BF</given-names></name><name><surname>Shi</surname><given-names>W</given-names></name><name><surname>Bond</surname><given-names>JH</given-names></name><name><surname>Schapiro</surname><given-names>M</given-names></name><name><surname>Panish</surname><given-names>JF</given-names></name><name><surname>Stewart</surname><given-names>ET</given-names></name><name><surname>Waye</surname><given-names>JD</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Colonoscopic polypectomy and long-term prevention of colorectal-cancer deaths</article-title><source>The New England Journal of Medicine</source><volume>366</volume><fpage>687</fpage><lpage>696</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1100370</pub-id><pub-id pub-id-type="pmid">22356322</pub-id></element-citation></ref></ref-list></back><sub-article article-type="editor-report" id="sa0"><front-stub><article-id pub-id-type="doi">10.7554/eLife.85264.sa0</article-id><title-group><article-title>Editor's evaluation</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Franco</surname><given-names>Eduardo L</given-names></name><role specific-use="editor">Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01pxwe438</institution-id><institution>McGill University</institution></institution-wrap><country>Canada</country></aff></contrib></contrib-group><related-object id="sa0ro1" object-id-type="id" object-id="10.1101/2022.12.23.22283887" link-type="continued-by" xlink:href="https://sciety.org/articles/activity/10.1101/2022.12.23.22283887"/></front-stub><body><p>This important study uses two well-established colorectal cancer models to estimate the potential impact of disruptions in screening caused by the COVID-19 pandemic. By dividing the population into separate cohorts based on age and pre-pandemic screening status, the authors provide convincing evidence for the adverse impact of delays in screening, switching regimens, and screening discontinuation. The finding that discontinuation has a much greater impact on screening-associated gains in life expectancy than shorter-term delays or switching of regimens suggests that access-related barriers to screening resumption may lead to the worsening of current disparities.</p></body></sub-article><sub-article article-type="decision-letter" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.85264.sa1</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Franco</surname><given-names>Eduardo L</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01pxwe438</institution-id><institution>McGill University</institution></institution-wrap><country>Canada</country></aff></contrib></contrib-group><contrib-group><contrib contrib-type="reviewer"><name><surname>Myers</surname><given-names>Evan</given-names></name><role>Reviewer</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03wfqwh68</institution-id><institution>Duke University Health System</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group></front-stub><body><boxed-text id="sa2-box1"><p>Our editorial process produces two outputs: (i) <ext-link ext-link-type="uri" xlink:href="https://sciety.org/articles/activity/10.1101/2022.12.23.22283887">public reviews</ext-link> designed to be posted alongside <ext-link ext-link-type="uri" xlink:href="https://www.medrxiv.org/content/10.1101/2022.12.23.22283887v1">the preprint</ext-link> for the benefit of readers; (ii) feedback on the manuscript for the authors, including requests for revisions, shown below. We also include an acceptance summary that explains what the editors found interesting or important about the work.</p></boxed-text><p><bold>Decision letter after peer review:</bold></p><p>Thank you for submitting your article &quot;Unequal Recovery in Colorectal Cancer Screening Following the COVID-19 Pandemic: A Comparative Microsimulation Analysis&quot; for consideration by <italic>eLife</italic>. Two peer reviewers have reviewed your article, and I have overseen the evaluation in the dual role of Reviewing Editor and Senior Editor. The following individual involved in the review of your submission has agreed to reveal their identity: Evan Myers (Reviewer #1).</p><p>Essential revisions:</p><p>As is customary in <italic>eLife</italic>, the reviewers have discussed their critiques with one another and with the editors. The decision was reached by consensus. What follows below is an edited compilation of the essential and ancillary points provided by reviewers in their critiques and in their interaction post-review. Please submit a revised version that addresses these concerns directly. Although we expect that you will address these comments in your response letter, we also need to see the corresponding revision clearly marked in the text of the manuscript. Some of the reviewers' comments may seem to be simple queries or challenges that do not prompt revisions to the text. Please keep in mind, however, that readers may have the same perspective as the reviewers. Therefore, it is essential that you amend or expand the text to clarify the narrative accordingly.</p><p><italic>Reviewer #1 (Recommendations for the authors):</italic></p><p>A clearly presented paper with compelling and intuitive (this is a good thing!) findings. I have only a few questions/suggestions:</p><p>1) LYG is clearly the appropriate primary outcome, but it would be of interest (and helpful to some policymakers) to have estimates of net/% changes in cancer cases and deaths.</p><p>2) Lines 304-311: I agree with this, but wouldn't it be possible to at least provide bounds based on the current age structure? Even crude weighted averages would be potentially compelling.</p><p>3) Lines 289-291: How would this be implemented? Would Medicare prioritize 65-year-olds with no previous screening? I agree that this is obviously the priority population, but how it might work is worth expanding a bit.</p><p>4) Finally, although beyond the scope of the paper, some discussion of the potential use of methods of distributional and/or extended cost-effectiveness analysis to address some of the equity issues raised here would be appropriate.</p><p><italic>Reviewer #2 (General comments and recommendations):</italic></p><p>Overall, the paper looks ok methodologically, and it addresses an important issue. The underlying models are not well described, but they have been published elsewhere and I assume extensively validated by being part of CISNET. The main shortcoming is that the effect of the pandemic is purely based on assumptions, rather than data – it would have been better if they had collected some information about how long patients put off screening during the pandemic (since it has been a few years already, this should not be difficult). But seeing that they've used a range of different assumptions, their approach seems acceptable.</p><p>The authors assume that short-term delays are a fixed duration for all patients, but in practice, this might be variable – e.g. perhaps patients with risk factors might be prioritised, or perhaps those with some clinical symptoms? Or alternatively, patients with good healthcare access (who might also be at lower risk) might have shorter durations. This is an area where collecting some data might be helpful. But again, this is a limitation rather than a fatal flaw – I think the paper as it stands is a valuable contribution.</p><p><italic>Essential points from the post-review interaction between reviewers:</italic></p><p>Rev 1: I agree with Rev 2's thoughts, which I think align with mine. The issue of prioritization that Rev 2 raises really needs to be discussed more--it's not at all clear to me how that would work in most US settings. It was a basic issue DURING the pandemic for things like elective surgery, and how systems could be put in place to equitably and efficiently handle it is a challenge. The other thing that would seem to be relatively straightforward to do would be to put some ranges around the potential impact given the current population age distribution--just take the model results for the different cohorts under different scenarios and estimate a weighted average given the age distribution of the US population in 2019-2020.</p><p>Rev 2: Agree with Rev 1's overall appraisal (good paper with some limitations). Also, Rev 1's point about prioritisation is an important one, both (i) the descriptive question (what kind of prioritisation did happen during the pandemic?) and (ii) the normative question (what kind of prioritisation SHOULD be put in place, to achieve efficient and equitable outcomes with reduced resources?) While the authors don't have the data to answer it precisely, it is an issue that deserves a bit more attention/discussion.</p></body></sub-article><sub-article article-type="reply" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.85264.sa2</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>Reviewer #1 (Recommendations for the authors):</p><p>A clearly presented paper with compelling and intuitive (this is a good thing!) findings. I have only a few questions/suggestions:</p><p>1) LYG is clearly the appropriate primary outcome, but it would be of interest (and helpful to some policymakers) to have estimates of net/% changes in cancer cases and deaths.</p></disp-quote><p>We thank the reviewer for this suggestion. We now present both suggested outcomes (absolute and relative CRC cases and deaths) as Supplementary files and include these results in our discussion. As a relative outcome, now we present model-projected Risk Ratios (RRs) for CRC cases and deaths relative to a no-disruption scenario.</p><disp-quote content-type="editor-comment"><p>2) Lines 304-311: I agree with this, but wouldn't it be possible to at least provide bounds based on the current age structure? Even crude weighted averages would be potentially compelling.</p></disp-quote><p>Estimating the population level effect is challenging because one would also have to know more (or make more assumptions) about the screening history for each age group. Estimating population-level outcomes was beyond the scope of this paper as it would require either assumptions that would be difficult to defend or data that are not available. We acknowledge this limitation in the Discussion section.</p><disp-quote content-type="editor-comment"><p>3) Lines 289-291: How would this be implemented? Would Medicare prioritize 65-year-olds with no previous screening? I agree that this is obviously the priority population, but how it might work is worth expanding a bit.</p></disp-quote><p>Healthcare prioritization is a thorny ethical trolley problem, and providing definitive prescriptive advice on this issue is beyond the scope of this paper; it would be infeasible to do justice to this topic in only a few sentences or even a few paragraphs. We have now rephrased that sentence to remove the previous normative connotation, and simply state that those that were previously uninsured should resume CRC screening to avoid the negative long-term effects projected in our study.</p><disp-quote content-type="editor-comment"><p>4) Finally, although beyond the scope of the paper, some discussion of the potential use of methods of distributional and/or extended cost-effectiveness analysis to address some of the equity issues raised here would be appropriate.</p></disp-quote><p>Thank you for this suggestion; we now mention this topic at the end of our discussion.</p><disp-quote content-type="editor-comment"><p>Reviewer #2 (General comments and recommendations):</p><p>Overall, the paper looks ok methodologically, and it addresses an important issue. The underlying models are not well described, but they have been published elsewhere and I assume extensively validated by being part of CISNET. The main shortcoming is that the effect of the pandemic is purely based on assumptions, rather than data – it would have been better if they had collected some information about how long patients put off screening during the pandemic (since it has been a few years already, this should not be difficult). But seeing that they've used a range of different assumptions, their approach seems acceptable.</p></disp-quote><p>We agree with the reviewer that using individual-level data to characterize the distribution of delays and other CRC screening disruptions would have been ideal, but that was outside of the scope of this paper.</p><disp-quote content-type="editor-comment"><p>The authors assume that short-term delays are a fixed duration for all patients, but in practice, this might be variable – e.g. perhaps patients with risk factors might be prioritised, or perhaps those with some clinical symptoms? Or alternatively, patients with good healthcare access (who might also be at lower risk) might have shorter durations. This is an area where collecting some data might be helpful. But again, this is a limitation rather than a fatal flaw – I think the paper as it stands is a valuable contribution.</p></disp-quote><p>The reviewer poses interesting questions on the potential correlation between risk, access, and delays that one might be able to address using microdata. For instance, a healthcare provider with access to individual-level data might be able to perform this analysis and investigate the hypothesis that delays were distributed differentially depending on risk factors. We now specifically note this as a limitation of our paper.</p><disp-quote content-type="editor-comment"><p>Essential points from the post-review interaction between reviewers:</p><p>Rev 1: I agree with Rev 2's thoughts, which I think align with mine. The issue of prioritization that Rev 2 raises really needs to be discussed more--it's not at all clear to me how that would work in most US settings. It was a basic issue DURING the pandemic for things like elective surgery, and how systems could be put in place to equitably and efficiently handle it is a challenge. The other thing that would seem to be relatively straightforward to do would be to put some ranges around the potential impact given the current population age distribution--just take the model results for the different cohorts under different scenarios and estimate a weighted average given the age distribution of the US population in 2019-2020.</p></disp-quote><p>As discussed above, estimating the population level effect is challenging because one would also have to know more (or make more assumptions) about the screening history for each age group. Simply taking a weighted average given the age distribution of the US population and applying it to our estimates would not result in a meaningful population-level estimate because:</p><p>– We only estimate populations that are exactly 50, 60, and 70 years old at the onset of the pandemic; and</p><p>– We only simulate a discrete, small set amongst the much larger set of real-world screening regimens.</p><p>We believe that the reasons above are sufficient to dissuade us from trying to produce population-level estimates that would lack in credibility.</p><p>As discussed before, we also added this as a limitation to our study (see comment 2, Reviewer 1)</p><disp-quote content-type="editor-comment"><p>Rev 2: Agree with Rev 1's overall appraisal (good paper with some limitations). Also, Rev 1's point about prioritisation is an important one, both (i) the descriptive question (what kind of prioritisation did happen during the pandemic?) and (ii) the normative question (what kind of prioritisation SHOULD be put in place, to achieve efficient and equitable outcomes with reduced resources?) While the authors don't have the data to answer it precisely, it is an issue that deserves a bit more attention/discussion.</p></disp-quote><p>We expanded the last paragraph of the Discussion section and added the issue of prescribing prioritization rules as a limitation of our paper. As discussed in our response to Reviewer 1, doing justice to the nuances of ethics and healthcare prioritization is beyond the scope of this paper. Moreover, we do not see a reason to dwell on that topic in this paper since we just demonstrated that short-term delays (i.e., interruptions to screening during the height of the pandemic when access to healthcare is interrupted) has little impact on lifetime effects. The major contributor to widening disparities is unequal access to healthcare for other reasons, including a long job loss or lack of insurance – not lack of healthcare capacity. We now make that point in the final paragraph of our discussion.</p></body></sub-article></article>